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Reports indicate that hyperglycaemia leads to development of kidney complications which result 
in sodium retention, decrease in glomerular filtration rate (GFR) and high blood pressure. Various 
biochemical processes such as polyol pathway, AGEs formation are thought to gives rise to a 
development and progression of these complications. Clinical trials show that there is currently no 
commercially available compound that lowers blood glucose concentration while alleviating 
diabetic nephropathy (DN). Current methods involve the use of ACE blockers which are associated 
with side effects. Previous reports in our laboratories indicate that triterpene constituents of 
Syzygium spp. such as oleanolic acid (OA) possess hypoglycaemic and renoprotetive effects in 
STZ-induced diabetic rats. The important question is whether MA, a related triterpene also 
possesses the same properties. MA is a hydrophobic triterpene and we therefore synthesised 
derivatives to improve solubility, bioavailability and efficacy. Accordingly this study was designed 
to investigate the effects of MA and related triterpene derivatives on renal function of STZ-induced 
diabetic rats.  
 
Materials and Methods 
MA was extracted from Syzygium aromaticum clove flower buds with dichloromethane and ethyl 
acetate (EA). The EA solubles rich in triterpenes were purified by silica gel column yielding a 
mixture of oleanolic acid (OA)/MA which was further purified and recrystallised from methanol 
and chloroform to obtain pure MA. The MA structure was confirmed by spectroscopic analysis 
using 1H and 13C NMR techniques. MA derivatives were then synthesized by introduction of 
phenylhydrazine (PH-MA), Cl-PH and F-PH at carbon 2 and 3. Diabetes was induced by 
intraperitoneal injection of streptozotocin (STZ) which was prepared in citrate buffer.  
The cell lines (MDBK and Chang) were challenged with 19 mmol of glucose and treated with 
various doses (40, 80 and 160 µmol/L) of either MA or PH-MA and incubated at 37 ºC in a 
humidified incubator with 5% CO2. Cell viability and glucose utilisation were monitored using 
CellTiter-Glo Luminiscent Cell Viability assay and OneTouch glucometer after 12, 24 and 48 h 
incubation period. Acute effects of MA on kidney function and MAP were investigated in 
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anaesthetised non-diabetic and STZ-induced diabetic animals. To investigate the influence of MA 
and related derivatives (PH-MA, F-PH and Cl-PH) on Na+ handling in the proximal tubule, animals 
received lithium 48 h prior the experiment. Following a 3½ h equilibration period, urine samples 
were collected at 30 min interval, over the subsequent 4 h for measurements of urine flow, Na+, 
K+, Cl-, creatinine and Li+ to assess proximal tubular handling of Na+ were recorded over 4 h post-
equilibration period of 1 h control, 1 h 30 min treatment as well as 1 h 30 min for recovery periods. 
In those animals in which the effects of either MA or derivatives were studied, MA (90 µg/min) 
or derivatives (22 µg/min) were added into the infusate containing creatinine for 1 ½ h treatment 
period. 
 
Blood glucose concentrations were also monitored in animals treated with MA and/or metformin 
for 5-weeks and these were measured 6 h after treatment. Food intake, water intake, urine output 
and weight were measured every third day at 09h00, 24 h after treatment. Urine sample collected 
during the 5-week study were used for evaluation of kidney function through measurements of 
Na+, K+, Cl-, creatinine and urea. Harvested organs after 5-weeks were used for investigation of 
oxidative status (MDA, SOD and GPx) in non-diabetic and STZ-induced diabetic rats. The 
harvested kidneys were also used to investigate the effects of MA expression on GLUT 1 and 2 
and expression of GLUT 4 was investigated on muscle tissue. 
 
Results  
Acute administration of MA (40 and 80 mg/kg) significantly (p<0.05) reduced blood glucose 
concentrations in non-diabetic and STZ-induced diabetic rats by comparison with respective 
control animals at corresponding time periods. MA (80 mg/kg, p.o.) was more effective in 
lowering blood glucose concentrations and the values were comparable with metformin. The 
lowest dose of MA (20 mg/kg, p.o.), however reduced blood glucose to values that did not reach 
statistical significance by comparison with the control at corresponding time periods. The same 
effects were observed in STZ-induced diabetic rats treated with MA for 5-weeks; however, the 
reduction in non-diabetic rats did not achieve statistical significance by comparison with the 
control. In addition, our results indicate that MA-treatment diminished the expression of GLUT1 
and GLUT2 in diabetic kidney. Interestingly, MA significantly decreased glucose utilisation by 
ix 
 
MDBK cells line.  An increase in GLUT 4 expression was observed in muscles tissue following 
treatment with MA. Treatment with MA (40 and 80 mg/kg, p.o.) for 5 weeks significantly (p<0.05) 
increased Na+ output and glomerular filtration rate (GFR) without influencing urine flow, K+, and 
Cl- output. Furthermore, MA at 40 and 80 mg/kg significantly (p<0.05) decreased mean arterial 
pressure (MAP) from the 3rd week until the end of the experimental period. Acute intravenous 
infusion of MA significantly (p<0.05) increased Na+ output, with a concomitant increase in 
fractional excretion of Na+ (FENa) and lithium (FELi) without influencing GFR. Acute infusion of 




Our results suggest that MA and PH-MA possess kidney ameliorative properties in part via 
inhibition Na+ reabsorption in the proximal and distal tubule. We speculate that MA and PH-MA 
increased Na+ excretion through inhibition of sodium hydrogen exchanger 3 (NHE3) and 
basolateral Na+-K+-ATPase which are known to increase reabsorption of Na+ in the proximal 
tubule. Interestingly, treatment of MDBK cells with MA and PH-MA diminished expression of 
epithelial sodium channels (ENaC), indicating that Na+ handling was not only the proximal tubule. 
These findings were in agreement with a decrease in plasma aldosterone following treatment with 
MA and PH-MA. Our results also showed that the elevated concentrations of MDA (marker of 
lipid peroxidation) in diabetic rat tissues of the liver, kidney and were restored within normal 
values after treatment with MA after 5-weeks. The reduction in MDA could be due to improved 
glycaemic levels and increased antioxidants such as SOD and GPx. Cell viability studies also 
revealed that the natriuretic effects of MA were not associated with toxicity. Although PH-MA 
exerted toxicity after 24 and 48 h treatment, we suspect that the doses used in this study were very 
high as they were the same as those of the parent compound.  
 
Summary 
In summary, the findings of this study suggest that MA and PH-MA possess kidney ameliorative 
properties in part via inhibition of Na+ reabsorption in the proximal and distal tubules. This was 
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evidenced by an increase in FENa and FELi and decreased expression of ENaC, which suggests that 
these triterpenes inhibit proximal tubular and distal tubular reabsorption. This, therefore, resulted 
in pronounced increase in urinary Na+ excretion without inducing any toxicity effects on the kidney 
and liver cell lines.  
 
Conclusion  
We provide the first report on multiple mechanisms that mediate natriuretic effects of MA and 
related triterpene derivatives. Additionally, this study indicates for the first time that MA reduced 
blood pressure while exerting no toxic effects to the kidney and liver cell lines. Taken together, 
the results suggest that MA and PH-MA indeed may alleviate some complications associated with 
diabetes mellitus.   
 
Future recommendations  
The future studies should investigate the effects of PH-MA on glucose homeostasis in STZ-
induced diabetic rats. These studies should also investigate the effects of MA on Na+ transporters 
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1.0 Preamble   
The focus of the investigations described in this thesis were to establish whether maslinic acid 
(MA) and related triterpene derivatives can improve impaired renal fluid and electrolyte handling 
of STZ-induced diabetic rats. Reports indicate that diabetes mellitus (DM) leads to impaired 
kidney function marked by decrease in glomerular filtration rate (GFR), sodium (Na+) retention 
and increased blood pressure. Clinical trials suggest that there is no effective treatment for diabetic 
nephropathy (DN) and this has become a serious medical challenge. However, angiotensin II (AII) 
receptor antagonists have been shown to be reno-protective in patients with DM. Despite the 
efficacy of the aforementioned treatments, patients still remain at high risk of complication even 
during high intensive therapy. Primary goal to prevent the onset of diabetic nephropathy (DN) is 
tight glycaemic control. We have reported that Syzygium spp-derived oleanolic acid (OA) lowers 
blood glucose concentration and ameliorates kidney function of streptozotocin (STZ)-induced 
diabetic rats. Guided by this fundamental observation we speculated that MA, a related triterpene 
possesses similar effects. However, important question is whether MA can improve the impaired 
renal function in diabetes. To further enhance the efficacy of MA a series of derivatives were 
synthesised. Research is indeed showing that most synthetic drugs derived from natural products 
ameliorate kidney function in diabetes. Accordingly, the focus of this study was to determine 
whether MA and related triterpene derivatives can improve the impaired renal fluid and electrolyte 
handling often seen in experimental animals and humans. In addition the study investigated 
whether MA influences renal expression of glucose and Na+ transporters in STZ-induced diabetic 
rats. High expression of these transporters has been implicated in the pathogenesis of DN. The 






1.1 Introduction/Literature review  
1.1.1 Diabetic nephropathy  
Hyperglycaemia leads to the development and progression of end-stage renal disease (ESRD), the 
principal cause of death as a result of diabetic nephropathy (DN). Multiple mechanisms that 
contribute to development and progression of DN include oxidative stress, protein kinase C (PKC), 
polyol/aldose reductase, advanced glycation end product (AGE)–receptor of AGE (RAGE) 
pathways and renin-angiotensin system (Arora and Singh, 2013). These pathways metabolize 
excess glucose to toxic metabolites which perturb intra-renal haemodynamics via glycosylation of 
intrarenal proteins that induce hyperfiltration and glomerular dysfunction (Whiteside and Dlugosz, 
2002). An increase in glucose fluxes through epithelial pathways result in the increased expression 
and activity of aldose reductase, protein kinase C, and transforming growth factor-β, which have 
all been implicated in causing DN (Wood and Trayhurn, 2003; Abisambra et al., 2013). To date 
there is no apparent common element linking these mechanisms. The clinical trials of inhibitors of 
these pathways in patients were all disappointing. Researchers have hypothesized that all of these 
mechanisms are linked to a common upstream event and that the failure to block all of the 
downstream pathways could explain the disappointing clinical trials with single-pathway 
inhibitors (Rodrigo and Rivera, 2002). Reports have established that all of these different 
mechanisms do reflect a single hyperglycaemia-induced process of the overproduction of 
superoxide by the mitochondrial electron transport chain which causes the oxidative stress (Evans 
et al., 2002). This study investigated whether treatment with MA can modulate the oxidative stress 
in diabetic kidneys. Hyperglycaemia induced oxidative stress is thought to mediate a wide range 
of renal impairments ranging from acute renal failure (Shah, 2001) obstructive nephropathy 
(Klahr, 2001) and glomerular damage (Kitamura et al., 2002). Thus, increased levels of 
malondialdehyde and F2-isoprostanes, two products of lipid peroxidation have been reported in 
various clinical settings associated with renal damage (Martín-Mateo et al., 1999), although most 
of these studies have been performed in rats or mice.  
Manifestation of these toxic metabolites result in various ultrastructural changes which include  
basement membrane thickening, glomerular and tubular hypertrophy, mesangial expansion, 
glomerulosclerosis and tubulointerstitial fibrosis (Parving et al., 2000). Whilst most attention has 
focused on glomerular changes, renal tubules are now increasingly recognized to play an important 
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role in the pathogenesis of DN (Magri and Fava, 2009). The proximal tubule plays a crucial role 
in the pathogenesis of diabetic kidney disease, being uniquely susceptible to a variety of metabolic 
and haemodynamic factors associated with diabetes (Bagby, 2007). The proximal tubules react to 
the different offences with a variety of incompletely understood changes such as tubular 
hypertrophy, tubular atrophy, and reduced organic ion transport (Thomas et al., 2005).  
 
1.2 Aetiology of diabetic nephropathy (DN)  
 
Early stages of DN are associated with about 30% increase in glomerular filtration rate (GFR) 
(Kalk et al., 2010). An increase in proximal tubular reabsorption has also been shown within the 
spectrum of the early changes observed in diabetic kidneys suggesting an alternative hypothesis to 
explain the increase in GFR. In normal and pathophysiological conditions, glomeruli and tubules 
are functionally linked to ensure maintenance of adequate extracellular volume and consequently 
systemic perfusion (Thomson and Blantz, 2008). Two mechanisms are involved in this process. 
Glomerulotubular balance modulates proximal tubular reabsorption according to changes in GFR 
in order to guarantee a constant percentage of tubular reabsorption of filtered solutes. This study 
focused on investigating whether MA and derivatives can decrease proximal tubular reabsorption. 
The mechanism mainly depends on parallel changes in peritubular capillary oncotic pressure that 
accompany changes in filtration fraction (Thomson et al., 2001). However, glomerulotubular 
balance is not fully efficient in maintaining fractional reabsorption constant. Due to the limitation 
of glomerulotubular balance, part of any change in GFR will pass along the nephron eliciting the 
tubuloglomerular feedback response, which will counteract some of the original disturbance. An 
initial reduction in proximal tubular reabsorption results to an increase in NaCl in the thick 
ascending limb of Henle and the distal tubule, which in turn lead to decrease in GFR.  Conversely 
a reduction in distal delivery driven by increased reabsorption in the proximal tubule induces an 
increase in single-nephron GFR. This study also focused on investigating whether treatment with 
either MA or derivatives influence transport proteins (ENaC) which modulate NaCl reabsorption 
in the distal tubule. Before dwelling too much on the pathology of DN, the following section 





1.2.1 Oxidative stress  
 
As mentioned in previous sections, evidence indicates that oxidative stress is the common 
denominator link for the major pathways involved in the development and progression of diabetic 
micro- as well as macrovascular complications of diabetes (Ha and Kim, 1999). The reactive 
oxygen species (ROS) are a family of molecules including molecular oxygen and derivatives, 
superoxide anion (O2), hydroxyl radical, hydrogen peroxide (H2O2), peroxynitrite (ONOO−), 
hypochlorous acid (HOCl), nitric oxide (NO) and lipid radicals. Many ROS possess unpaired 
electrons and thus are regarded as free radicals. Excessive amounts of ROS, after surpassing 
various endogenous anti-oxidative defensive mechanisms, oxidize various tissue biomolecules, 
such as, DNA, protein, carbohydrates and lipids; and this devastating state has been commonly 
referred to as an oxidative stress (Brownlee, 2001; Papaharalambus and Griendling, 2007). In 
mammalian cells, potential sources of ROS include mitochondrial respiratory chain, xanthine 
oxidase, NADH/NADPH oxidases, NO synthase and certain other haemoproteins. These different 
sources of ROS are operative under hyperglycaemic state and are considered to play a significant 
role in pathogenesis of DN (Forbes et al., 2008). The increased production ROS is thought to 
overwhelm  the endogenous anti-oxidative defense systems in the body (Ceriello et al., 2000). The 
oxidative stress is regarded as a common and major factor that couples hyperglycemia with 
vascular complications via two mechanisms first, the metabolic modifications of target tissue 
molecules and second, the alterations in the renal hemodynamics.  
 
One of the most important mechanisms that leads to overproduction of ROS is the polyol-pathway. 
The polyol pathway is based on a family of aldo-keto reductase enzymes that can use as substrates 
a wide variety of carbonyl compounds and reduce these by NADPH to their respective sugar 
alcohols (polyols) (Brownlee, 2001). Aldose reductase (AR) converts excess glucose to sorbitol 
which is then oxidized into fructose by sorbitol dehydrogenase (SDH), with NAD+ as a cofactor. 
Aldose reductase is found in tissues such as nerve, retina, lens, glomerulus, and vascular cells. In 
many of these tissues, glucose uptake is mediated by insulin-independent GLUTs intracellular 
glucose concentrations, therefore, rise in parallel with hyperglycemia. Several mechanisms have 
been proposed to explain how hyperglycaemia-induced increases in polyol pathway flux could 
damage the tissues involved. The most cited is an increase in redox stress caused by the 
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consumption of NADPH. Depletion of NADPH, a cofactor required to regenerate reduced 
glutathione (GSH) which is an important scavenger of ROS is thought to exacerbate intracellular 
oxidative stress. (Brownlee, 2001). Indeed, overexpression of human aldose reductase is 
implicated in various complications such as DN (Rodrigo and Rivera, 2002).  
 
1.2.2 Oxidative stress in diabetic kidney  
 
The kidney is thought to be vulnerable to early structural and functional damage caused by 
hyperglycaemia induced oxidative stress. The kidney may be particularly vulnerable to early 
structural and functional damage caused by hyperglycemia-induced oxidative stress (Singh et al., 
2011). Several factors might contribute directly or indirectly to this susceptibility. The glomerular 
mesangial cells and tubular cells do not require insulin for glucose uptake and consequently have 
no control over glucose movement across the cells (Heilig, 1995). Chronic hyperglycemia in the 
diabetic kidney stimulates the production of AGEs, the polyol pathway and activation of PKC, all 
of which lead to increased ROS formation and oxidative stress (Pacher et al., 2005 ). Renal cells 
such as glomerulus, tubules and fibroblasts express NADPH oxidase and contribute to ROS 
formation in small amounts in the healthy state. In chronic hyperglycemia, dysfunctional renal 
cells can increase ROS generation which may enhance renal tissue injury. In addition to structural 
and functional derangements, presence of excessive ROS in the renal milieu can promote 
dysregulation of renal medullary blood flow leading to renovascular hypertension. Furthermore, 
hyperglycemia-induced oxidative stress plays a major role in extracellular matrix expansion, since 
high glucose-induced collagen production in cultured rat mesangial cells was effectively prevented 
by two antioxidants, taurine and vitamin E (Trachtman et al., 1993). Studies have also 
demonstrated that hydroxyl radical scavengers at concentrations inhibits high glucose-induced 
lipid peroxidation, suppressed TGF-β1 and fibronectin mRNA expression and protein synthesis 
by mesangial cells cultured under high levels of glucose (Ha et al., 1997). TGF-β is a final common 
mediator of the principal lesions of renal disease in diabetes mellitus such as renal/glomerular 
hypertrophy and extracellular matrix expansion (Ziyadeh and Han, 1997). Hydrogen peroxide 
increases TGF-β1 and fibronectin production in mesangial cells, further suggesting an important 




1.3 Proximal tubular reabsorption 
We have shown that that OA inhibits reabsorption of sodium in the proximal tubule using lithium 
clearance studies (Madlala et al., 2012). The proximal tubule is known to reabsorb about 50% of 
the filtered Na+. Sodium hydrogen transporter type 3 (NH3) is the most predominant hence lithium 
clearance studies were carried out to investigate proximal handling of Na+. The (NHE's) are a 
family of transmembrane proteins that mediates electroneutral transport of Na+ for H+ across 
cellular membranes. The reabsorption process is controlled by different regulatory factors which 
include glomerulotubular balance, angiotensin II, endothelin, sympathetic innervation, parathyroid 
hormone, dopamine and acid base status. The apical membrane Na+/H+ exchanger NHE3 is 
responsible for quantitative transcellular NaCl reabsorption, and two thirds of the transcellular 
NaHC03 reabsorption, as well as for 70% of H
+ secretion in the proximal tubule (Swasti et al., 
2007). This transport protein is regulated by a large variety of hormones, growth factors and 
physical parameters, including osmotic and haemodynamic factors. NHE3 is stimulated by 
hormones such as angiotensin II, endothelin and insulin and is inhibited by dopamine, parathyroid 
hormone and angiotensin. This study also investigated the effects of MA and derivatives on the 
plasma concentrations of renally active aldosterone and arginine vasopressin (AVP) in STZ-
induced diabetic rats. Insulin has been shown increase NH3 expression by  facilitating Na+ 
reabsorption in the proximal tubule cells (Klisic et al., 2002). In addition to NH3, cotransporter 
type II (NaPi-2)  is responsible for reabsorption of K+ coupled to Na+ (Vogel et al., 2000). An 
increase in phosphate reabsorption by NaPi-2 is concomitant with increase sodium reabsorption in 
the proximal tubule given no changes in other apical transporter activity. Interestingly, insulin has 
also been shown to increase K+ reabsorption in the proximal tubule brush border from dog kidney 
(Swasti et al., 2007). This therefore, indicates the importance of insulin in regulation of kidney 
function. Na+ handling is not only limited to the proximal tubule, the next section explains the 
importance of other transport proteins in renal function. This study investigated the effects of MA 






1.3.1 The loop of Henle 
The loop of Henle is a heterogeneous nephron segment which reabsorbs about 30-40% of the 
filtered load. This segment consists of the straight portion of the proximal tubule (pars recta), the 
descending and ascending thin limbs, and the thick ascending limb (TAL). In the TAL 20% of Na+ 
of the filtered load is reabsorbed but water is not. This therefore, creates a steep osmotic gradient 
in the medullary interstitium which permits vasopressin-dependent water reabsorption in the 
collecting duct. Most of sodium transport in the TAL results directly or indirectly from Na+-K+-
2Cl– cotransport BSC1/NKCC2 in efficiently work in the presence of  K+ to recycle across the 
apical membrane through a K+ channel (ROMK) and chloride to exit basolaterally through a 
chloride channel (Mullins et al., 2006). Potassium recycling creates an electrical potential 
difference which drives the reabsorption of cations through the paracellular pathway. 
NKCC2/BSC1 increase sodium reabsorption and through counter-current multiplication, increase 
urinary concentrating ability (Dongun et al., 2002). These findings tend to support the hypothesis 
that the increases NKCC2/BSC1 proteins during uncontrolled diabetes are compensatory changes 
that prevent a progressive decline in urinary concentrating ability despite the continuing osmotic 
diuresis (Dongun et al., 2002). Interestingly, several studies have been conducted to demonstrate 
increased sodium or chloride reabsorption in response to insulin in this segment (Swasti et al., 
2007).  
 
1.3.2 The distal tubule and collecting duct  
Sodium reabsorption in the early distal tubule (DCT1 and DCT2) is mediated by the thiazide-
sensitive NaCl cotransporter (TSC), ENaC and to a lesser extent, by sodium-hydrogen exchange 
(NHE-2). The remaining reabsorption is achieved in the connecting tubule and cortical collecting 
duct via ENaC. This is a segment where fine tuning of sodium reabsorption occurs and this is 
controlled by aldosterone.  The actions of insulin in the DCT are not clear since this segment is 
short and hence not readily perfusable in most species. However, research indicates that the DCT 
has  a fairly high abundance of insulin binding sites (Swasti et al., 2007) suggesting that there is a 
clear potential for regulation of electrolyte transport. This suggests the importance of insulin in the 
systemic circulation, lack of it in case of diabetes mellitus results in several adverse effects. This 
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study, therefore, also investigated the effects of MA and derivatives on expression of ENaC in 
MDBK cells. 
 
1.3.3 Expression of glucose/sodium transporters in diabetes mellitus 
The increase in proximal tubular reabsorption and consequent reduction in distal delivery of 
sodium chloride in patients with types 1 and 2 DM was originally was described more than 20 
years ago in studies using lithium clearance (Ditzel et al., 1989). Based on these observations, a 
decrease in distal sodium delivery is thought to contribute to diabetic glomerular hyperfiltration 
through a reduction in tubuloglomerular feedback–mediated vasoconstriction. Subsequently, 
micropuncture studies in diabetic rats confirmed that increased proximal tubular reabsorption has 
a major role in the development of glomerular hyperfiltration in the early stages of DM (Thomson 
et al., 2001). In these studies, increased proximal tubular reabsorption of chloride anions and 
sodium and potassium cations led to a 20%-28% reduction in the concentration of these ions in the 
distal tubule compared with non-diabetic rats. Indeed, clinical studies show a higher prevalence of 
glomerular hyperfiltration associated with enhanced proximal sodium reabsorption in Africans 
with impaired fasting glucose or type 2 DM (Pruijm et al., 2010). Most of the filtered glucose is 
recovered by tubular reabsorption to protect the individual against wide variations in glucose 
supply and demand. Glucose is removed from the tubular lumen by active transport at the level of 
the proximal segments. The amount of glucose reabsorbed is proportional to the filtered load and 
hence depends on plasma glucose. The ability of the proximal tubule to reabsorb glucose increases 
with increments in the filtered load secondary to higher GFR or plasma glucose levels. When the 
filtered load reaches the maximal transport level, any additional increase results in glycosuria 
(glucose above 0.5 g/day). Experimental studies in animal models described two different glucose 
transporters located in the proximal tubule (Barfuss and Schafer, 1981) a “high-flux low affinity” 
transporter (SGLT2, located in the S1 segment) and a “low-flux high-affinity” transporter (SGLT1, 
located in the S3 segment). The S1 segment reabsorbs the largest proportion of the filtered glucose 
and sodium load, while the remaining 10% is reabsorbed by the S3 segment (Vallon et al., 2011). 
In diabetic patients glycosuria is limited by upregulation of tubular glucose reabsorption (Quamme 
and Freeman, 1987). Early experiments in human kidney tubular cells harvested from urine of 
patients with type 2 DM demonstrate an increase in the expression, protein concentration, and a-
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methylglucose transport capacity of SGLT2 compared with non-diabetic individuals (Rahmoune 
et al., 2005). This indicates that high expression of SGLT2 is involved in pathogenesis of diabetic 
nephropathy. More recent insights have been provided by studies in non-diabetic mice lacking 
expression of SGLT1 (SGLT2/2). These studies demonstrated that SGLT1 is required for complete 
reabsorption of filtered glucose in the kidney (Gorboulev et al., 2012). Furthermore, during SGLT2 
inhibition, the glucose load to the SGLT1-expressing S2/S3 segments of the proximal tubule is 
enhanced and a compensatory increase in SGLT1-mediated transport occurs.  The contribution of 
SGLT1 may explain, at least in part, why SGLT2 inhibition is associated with excretion of only 
50%-60% of filtered glucose. These results are also consistent with the observation that combined 
SGLT1 and SGLT2 knockout is associated with higher glucose excretion and improved glycaemia 
control compared to inhibition of SGLT2 alone. The bulk of filtered glucose is ∼90% reabsorbed 
by the low-affinity/high-capacity sodium glucose cotransporter (SGLT) 2 located in the S1 
segments of proximal tubule (Tabatabai et al., 2009). Residual glucose is then absorbed by the 
high-affinity/low-capacity SGLT1 in the S3 segment. Transcellular glucose transport is facilitated 
by two basolateral membrane glucose transporters: the low-affinity GLUT2 in the S1 segment and 
the high-affinity GLUT1 in the S3 segment (Tabatabai et al., 2009). A study in humans with type 
1 diabetes showed a significant increase in the renal transport maximum of glucose (Wood and 
Trayhurn, 2003). In addition, glucose transport in the diabetic kidney is upregulated and has been 
implicated in the pathogenesis of progressive DN. Renal tubular glucose reabsorption mediated by 
facilitative glucose transporter (GLUT) proteins and energy-dependent sodium glucose luminal 
transporters. Long-term diabetes has been reported increase GLUT1 levels in the renal proximal 
tubules and expression indicating that this transporter plays an important role in glucose 
reabsorption (Linden et al., 2006). Inhibition of GLUT 1 and GLUT 2 transporters has therefore 
become another approach for ameliorating diabetes and kidney function. To establish the 
mechanism through which MA exerted hypoglycaemic effects, expression of GLUTs was 
investigated in STZ-induced diabetic rats. The following section will further describes other 







1.3.4 The renin-angiotensin system (RAS)  
 
Reports indicate that the intrarenal renin-angiotensin system (RAS) is activated by hyperglycaemia 
leading to synthesis of kidney Ang II (Burns, 2000). Ang II is thought to increase sodium 
reabsorption by influencing various transporters involved in Na+ handling (Riquier-Brison et al., 
2010). Suppressing RAS activity in patients with DM using either an angiotensin-converting 
enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) slows the decline in kidney 
function. ARBs have been found to be effective throughout the entire spectrum of DN with greater 
efficacy in terms of nephroprotection when therapy is started early in the course of the disease 
(Brenner et al., 2001; Lewis et al., 2001). Measurements of parameters such as GFR, electrolytes 
handling and fractional excretion of lithium give an idea of what MA and derivatives do on RAS 
related complications of the kidney. This will helps us explore other mechanisms that these 
triterpenes may use to ameliorate kidney function in diabetes. Various classes of agents such as 
oral hypoglycaemic agents, insulin, anti-RAS, and diuretics are currently available for the 
prevention and treatment of DN however, use of these agents can be limited by side effects. More 
importantly there has been no substantial improvement in the prognosis of DM despite increasing 
awareness and screening of DM and implementation of more intensive and personalized therapies 
in these patients (Rossing and de Zeeuw, 2011). Thus, new therapeutic strategies are desperately 
needed to limit the burden of DM-induced kidney diseases and associated morbidity and mortality. 
The following section describes various methods for management of DN.  
 
1.3.5 Aldosterone  
A growing interest in understanding the effects on aldosterone on kidney function and diabetes 
mellitus has been explored over the years. Aldosterone is a steroid hormone that is primarily 
produced in the zona glomerulosa, the outer layer of the adrenal cortex. Effects of aldosterone are 
known to promote sodium (Na+) retention and potassium (K+) loss in various sites of the kidney 
which include sites including the distal tubule, collecting duct of the nephron, salivary and sweat 
glands and colon. Sodium crosses the outer membrane of polarized cells via the amiloride-sensitive 
sodium channel (ENaC) and reaches then the plasma compartment via the Na+, K+ATPAse of 
inner membrane (Tomlinson et al., 1992). The latter step thus promotes potassium excretion, and 
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aldosterone receptor antagonists have been mainly used in clinical practice as potassium-sparing 
diuretics. Reports indicate that aldosterone may contribute to tissue injury through mechanisms 
beyond influence on blood pressure (Tomlinson et al., 1992). Studies also show that type 1 diabetes 
leads to elevation of plasma aldosterone levels, which fell sharply after administrations of 
angiotensin receptor blocker. This study therefore, also investigated the effects of MA and 
derivatives on plasma aldosterone levels in STZ-induced diabetic rats.  
 
1.4 Current methods used to manage DN 
The major antihypertensive drug classes that are widely used include thiazide diuretics, 
angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β-
blockers, central sympatholytic agents and calcium channel antagonists. Other newly developed 
drugs include GLUT 2 and NHE3 inhibitors. The following section further describes these 
conventional treatments.  
 
1.4.1 GLUT transport inhibitors  
The insulin-responsive facilitative glucose transporters SGLT1 and GLUT1 found in the proximal 
convoluted tubule are responsible for re-absorbing filtered glucose from the tubule back into 
circulation. These co-transporters are up-regulated in the diabetic kidney (Marks et al., 2003) and 
result in greater re-absorption of glucose and thus exacerbating the pre-existing hyperglycaemia 
(Abdul-Ghani and Defronzo, 2014). This led us into evaluating whether our triterpenes can inhibit 
reabsorption of glucose in renal tubules and therefore lead to hypoglycaemia. Administration of 
SGLT2 inhibitors in diabetic patients produces both dose-dependent glycosuria and a significant 
reduction in plasma glucose concentrations (Wood and Trayhurn, 2003). Inhibition of SGLT2 
transport resets the system by lowering the threshold for glycosuria eventually correcting the 
hyperglycaemia. This decreases insulin resistance in muscle by augmenting insulin signaling, 
GLUT4 and glycogen synthase activity (Brosius and Heilig, 2005). In the liver correction of 
hyperglycaemia decreases glucose- 6-phosphatase and pyruvate carboxykinase activity, which 
results in decreased gluconeogenesis and total hepatic glucose production, with a resulting 
decrease in fasting plasma glucose levels (Rahmoune et al., 2005). 
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Inhibiting glucose transporters (GLUT) transporters that facilitate glucose reabsorption has been 
promising in management of kidney diseases related to diabetes. Under normal circumstances 
almost all of the reabsorbed glucose is reabsorbed by the proximal tubule back of the nephron 
(Chao and Henry, 2010). Glucose is reabsorbed by sodium-glucose co-transporters (SGLTs) and 
GLUTs (Chao and Henry, 2010). SGLT2 and GLUT2 are located in the early portion of the 
proximal convoluted tubule of the renal nephron and are responsible for the majority of glucose 
reabsorption from tubule back into the circulation (Chao and Henry, 2010; Vallon et al., 2011). 
Other glucose transporters such as SGLT1 and GLUT1 are present in the distal portion of the 
proximal tubule account for reabsorption of additional glucose. These co-transporters are up-
regulated in the diabetic kidney (Vestri et al., 2001 ) and result in greater re-absorption of glucose 
and thus contributing to the pre-existing hyperglycaemia. The up-regulation of these transporters 
has been implicated in the pathogenesis of diabetic nephropathy (Dominguez et al., 1994). 
Accordingly, we investigated the effects of MA and derivatives on renal expression of glucose 
transporters of STZ-induced diabetic rats. This study was designed to establish whether 
administrations of MA and derivatives can modulate kidney dysfunction associated with diabetes 
mellitus as assessed by effects on renal fluid and electrolyte handling in STZ-induced diabetic rats.  
The SGLT2 inhibitors therefore block reabsorption of glucose into circulation facilitating 
excretion of glucose hence decrease plasma glucose (List and Whaley, 2011). Moreover, because 
the mechanism of action of SGLT2 inhibitors does not depend on the presence of insulin, the 
efficacy of SGLT2 inhibitors would not be primarily affected by the magnitude of insulin 
resistance or impairment of pancreatic β-cell function that accompanies type 2 diabetes 
progressions. Reports also indicate that combination of SGLT2 inhibitors with other anti-diabetic 
compounds such as insulin can improve glycaemic control. Some of the SGLT2 inhibitors such as 
dapagliflozin and canagliflozin are in clinical trials (Edward and Chao, 2014). They have been 
shown to decrease systolic and diastolic blood pressure (Ferrannini et al., 2010; Amin et al., 2011). 
Phlorizin inhibits SGLTs and suppresses renal glucose reabsorption, resulting in an increased 
urinary excretion of glucose and a reduction of plasma glucose levels in diabetic model animals. 
This decrease in blood pressure may be related to SGLT2 inhibitor–induced diuresis and body 
weight changes. Such findings indicate that inhibition of SGLTs and GLUTs is of biological 
importance in management of diabetes mellitus. These inhibitors have been found to induce weight 
loss in type 1 diabetic patients. This could work as a disadvantage as this inhibitor can exacerbate 
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this weight loss. Valentine, 2012 suggested that these inhibitors might work better when combined 
with other anti-diabetic drugs (Valentine, 2012). This could however, be of a challenge to the 
general population in developing countries. Therefore, there is a need to look into other therapeutic 
interventions that would be of benefit to everyone. This study also investigated whether MA and 
derivatives have effects on GLUT transporters.  
 
1.4.2 Sodium transport inhibitors  
An absence of insulin or a substantial decrease in the activity of insulin at the cell level leads to 
impaired glucose uptake from plasma, hyperglycaemia, and glucosuria. Studies indicate that STZ-
induced diabetic rats increase protein expression of the majority of primary apical sodium transport 
proteins of the thick ascending limb (TAL) through the collecting duct (CD), including NKCC2, 
NCC, and the β-, α, γ subunits of ENaC (Figure 1) (Song et al., 2003). Hyperglycaemia has also 
been shown increase expression of sodium hydrogen transporter 3 (NH3) which is abundant in the 
proximal tubule (Riazi et al., 2006). High expression of these transporters lead to Na+ reabsorption 
and therefore retention of Na+. An inability to excrete sodium leads to increased blood pressure in 
humans and experimental animals. To date there is no treatment has been shown to lower blood 
glucose while inhibiting any of the above mentioned transport proteins. In our laboratory we  have 
shown that OA-evoked natriuretic effects are due to inhibition of sodium reabsorption in the 
proximal tubule as shown by lithium clearance studies (Madlala et al., 2012) suggesting that OA 
attenuating expression of NH3 transporters. This study, therefore, investigated whether treatment 
with MA and derivatives can down regulate expression of these transporters in diabetic rats. The 
question that remains unclear is whether this Na+ handling is only limited to the proximal tubule 
or to other segments of the nephron particularly the distal tubule (DCT). Sodium reabsorption in 
the early distal tubule (DCT1 and DCT2) is mediated by the thiazide-sensitive NaCl cotransporter 
(TSC) and to a lesser extent by sodium-hydrogen exchange (NHE-2). The remaining reabsorption 
is achieved in the connecting tubule and cortical collecting duct via ENaC. This is a segment where 
fine tuning of sodium reabsorption occurs and this is controlled by aldosterone. To further 
elucidate this mechanism we investigated effects of MA and derivatives on expression of at ENaC 





Figure 1: Expression of various transport proteins responsible for electrolyte and fluid handling. 
For our current research interest we focused mostly on the proximal tubule and distal tubules 
shown in blue. Proximal convoluted tubule: NOPi, NH3; distal tubule: ENaC and collecting duct: 
EnaC transporters.  
 
1.4.3 Insulin and synthetic drugs   
The goal in the management of diabetes mellitus is not only on maintaining optimal blood glucose 
control, but also alleviating associated complications. There is sparse information with regards to 
the effectiveness of current diabetes conventional therapy in the prevention or alleviation of renal 
complications associated with diabetes mellitus. However, insulin has been shown to be anti-
natriuretic (Sampanis, 2008) agent  increasing the activity of ENaC and NCC activity hence 
leading to Na+ retention in diabetes (DeFronzo et al., 1975).  
Most of the synthetic drugs influence the haemodynamic factors that alter GFR and also the 
pathways involved in the development of the DN (Mogensen et al, 2000). Furthermore, drugs that 
interfere with the different pathways involved in the development of DN preserve the structure of 
the kidneys. These drugs may inhibit formation of advanced glycation end products (AGE’s) 
(Jandeleit-Dahm, 2004) or inhibit AGE signal transduction (Hartog et al., 2007).  Additionally, 
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some drugs have been shown to decrease electrolyte reabsorption and these include beta-blockers, 
alpha 1-blockers, alpha 2-adrenoceptor agonists and calcium channel-blockers (Heintzen and 
Strauer, 1994). 
 
1.4.4 ACE inhibitors  
Angiotensin II inhibitors have been developed and investigated as therapeutic intervention for 
management of in DN (Yu and Khraibi, 2008). ACE inhibitors such as captopril, lisinopril, 
imidapril, ramipril, perindopril, cilazapril, benazapril, trandolapril, enalapril and fosinopril and 
AT1 receptor blockers such as losartan, irbesartan, olmesartan and candisartan have been observed 
to have therapeutic potential in the treatment of DN in numerous experimental and clinical studies 
(Giacchetti et al., 2005). ACE II is a vasoconstrictor that also leads to retention of sodium in 
experimental animals. Enalapril has previously been shown to inhibit sodium reabsorption in the 
proximal tubule suggesting that this inhibitor could have beneficial effects in diabetic animals 
(Simaratanamongkol et al., 2014). However, synthetic ACE inhibitors produce some side effects 
such as coughing, rashes and taste aversion. There is therefore, a need for new natural ACE 
inhibitors that may be safer and also more economical to use  (Simaratanamongkol et al., 2014). 
Natural products have attracted much interest due to their lack in toxicity and affordability in 
developing countries.  Several plant extracts, such as those from Glycine max (Rho et al., 2009) 
Cassia tora (Hyun et al., 2009) Rosa damascene (Kwon et al., 2010) Curcuma longa (Bhullar et 
al., 2013) and Lactuca sativa (Lagemann et al., 2012) have been reported to possess ACE 
inhibiting properties. Interestingly Olea lancea lam, a plant extract that is rich in triterpenes such 
as MA has also been found to inhibit ACE in vitro improving renal injury (Hansen et al., 1996). 
This, therefore, shows that plant derived extracts could be used as alternative methods for 
management of kidney dysfunction that arise due to DM.  
 
1.4.5 Drugs with antioxidant properties  
In diabetes, hypoinsulinaemia increases the activity of the fatty acyl coenzyme A oxidase, an 
enzyme which initiates β oxidation of fatty acids resulting in lipid peroxidation. Increased lipid 
peroxidation impairs membrane functions by decreasing membrane fluidity and changing the 
16 
 
activity of membrane-bound enzymes and receptors. The lipid peroxidation products (lipid radical 
and lipid peroxide) are harmful to the cells in the body and are associated with atherosclerosis, 
brain and kidney damage (Zhang and Kwong-Huat Tan, 2000). Therefore, this research also 
investigated whether triterpenes can improve the oxidative status seen in diabetes mellitus. 
Research indicates that antioxidant treatment with vitamins C and E improves renal function, 
lessens renal injury, and decreases arterial pressure in Dahl salt-sensitive hypertension (Tian et al., 
2005). Reports indicate that several plant extracts modulate diabetes associated oxidative stress 
processes (Pari and Latha, 2004). Against this background are observations that phytochemicals 
containing quercetin and flavonoids decrease blood glucose concentrations and oxidative stress in 
experimental diabetes (Azuma et al., 2007). In this study, we focused on the effects of MA on 
oxidative stress in the liver, heart and kidney of STZ-induced diabetic rats.  The decline in renal 
function of diabetic patients may be as a result of excess glucose in the kidneys. This excess 
glucose concentration may indirectly activate pathways within the kidney such as the polyol 
pathway and accumulation of advanced glycation end products (AGEs) (Cooper et al., 2001). 
Some findings suggest that the kidneys’ susceptibility to oxidative stress during early stages of 
diabetes mellitus may be an important factor in development of diabetic nephropathy (Jakus, 
2000).  
 
1.5 Medicinal plants 
Syzygium aromaticum is traditionally used for treating burns, dental care to relieve pain and to 
treat gum infections when used at high concentrations (Prashar et al., 2006). Pharmacological 
studies revealed that this is due to high concentration of euginol present in the plant extract.  
Reports also indicate that this extract contains a number pentacyclic triterpene including betulinic 
acid (BA) ursolic acid (UA), oleanolic acid (OA) and maslinic acid (MA). These triterpenes have 
gained considerable interest because of their multiple pharmacological effects which include anti-
HIV (Fujioka et al., 1994), antiviral (Pavlovaa et al., 2003) and anticancer (Fulda, 2008). We have 
previously shown that medicinal plants and their bio-active compounds acid (OA) isolated from 
Syzygium cordatum (S. cordatum), Syzygium aromaticum (S. aromaticum) may have beneficial 
effects on some of the processes that are associated with renal derangement (Madlala et al., 2012). 
Studies in our laboratory indicate that OA, a related triterpene does not only reduce blood glucose 
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concentrations, but also has beneficial effects on the kidney through the amelioration of GFR and 
increasing Na+ excretion rate in animals that have been observed to retain Na+ Hoek (Hoek et al., 
2008; Madlala et al., 2012). The increase in Na+ excretion also accompanied by a concomitant 
decrease in blood pressure (Madlala et al., 2012). OA has also shown the ability to decrease plasma 
creatinine with a concomitant increase in GFR (Mapanga et al., 2009). MA has previously been 
shown reduce blood glucose concentration in partially diabetic rats.  
 
1.5.2 Other medicinal plants  
Natural products have always been an ideal source of drugs and many of the currently available 
drugs have been derived directly or developed from plants (Narender et al., 2013). Plant-derived 
active chemical compounds like terpenoids, flavonoids, alkaloids, guanidines, steroids, 
carbohydrates and amino acids exhibit activity against diabetes mellitus (Narender et al., 2013). 
Metformin is currently used as anti-diabetic agent in the treatment of diabetes. Metformin and 
related analogues were synthesized on the basis of a natural product, galegine, which was isolated 
from the seeds of Galega officinali (Bailey and Day, 1989). The ethnobotanical information reports 
that about 800 plants may possess anti-diabetic potential (Puranik et al., 2010). Our goal is not 
only to reduce blood glucose concentrations, but to also ameliorate complications that arise in 
diabetes. Studies in our laboratory have investigated whether  ethno-botanic plants can improve 
the impaired renal function often seen in diabetes (Musabayane, 2012). Results observed showed 
that Hypoxis hemerocallidea corm aqueous extract (APE) had hypoglycaemic effects, but may 
have deleterious effects on kidney function (Gondwe et al., 2008). However, other studies from 
our laboratories have shown that Opuntia megacantha leaf hypoglycaemic effects reversed the 
inability of the kidney to excrete Na+ in STZ diabetes mellitus (Musabayane et al., 2007) 
suggesting that this plant may be beneficial in diabetes management. Plants such as Sclerocarya 
birrea [(A. Rich) Hochst.] [Anachardiaceae] Helichrysium ceres (Gondwe et al., 2008) and 
Syzygium cordatum (Mapanga et al., 2009)   have been shown to have reno-protective effects in 
diabetic animals. Other medicinal plants have been demonstrated to have anti-diabetic and 





Garlic (Allium sativum L., Liliaceae) is a well-known as a food flavouring agent that has been used 
since ancient time. In the past decade some protective effects of garlic have been well established 
by epidemiological studies and animal experiments. Commercially available garlic preparations in 
the form of garlic oil, garlic powder, and pills are widely used therapeutic purposes, including 
lowering blood pressure and improving lipid profile (Reuter, 1995; Poonam et al., 2013). Several 
studies have investigated diuretic effects of A. sativum in anaesthetized animals Pantoja 
(Sharafatullah et al., 1986; Pantoja et al., 1991). A powdered extract of A. sativum increased urine 
volume (UV) and urinary Na+ (UNa) excretion rate in experimental animal models. Blood pressure 
was also decreased by this extract. The second trial a purified fraction of A. sativum was 
intravenously injected and increased UV and UNa in a dose-dependently manner with a 
concomitant decrease in arterial blood pressure (Pantoja et al., 2000), The natriuretic effects of A. 
sativum was suggested to be via inhibition of kidney membrane N+, K+- ATPase. These studies 
demonstrated the effects of medicinal extracts on kidney function. Our study also aimed at 
investigating the effects of MA and derivatives on kidney function.  
 
Zea 
Zea mays L. (Gramineae) is commonly known as corn silk and has been used in folk medicine as 
a decoction for diuretic treatment. This plant extract has been shown to possess anti-
hyperglycaemic and kidney ameliorative properties in diabetic animals (Suzuki et al., 2005). 
Additionally, Zea demonstrates anti-hypertensive and anti-diabetic properties in the treatment of 
renal disease (Velazquez et al., 2005). This plant extract has also been shown to prevent formation 
of kidney stones in experimental animals (Maksimovic et al., 2004; Andrade-Cetto and Heinrich, 
2005). Studies by Ribeiro et al. showed UV was significantly increased after  treatment  (Ribeiro 
et al., 1988). These effects were seen after 1 day of treatment and were sustained throughout the 
course of treatment (Maksimovic et al., 2004). No changes in serum potassium, urea and creatinine 
were observed (Evans et al., 2002). These findings demonstrate an important relationship between 
treatment of diabetes and that of renal function using medicinal plants. For more information see 
Table 1.  
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1.6 Maslinic acid   
MA is a natural pentacyclic triterpene found in many plant species, but abundant in olive fruit skin 
(Qiu et al., 2009). MA (2a,3b-2,3-dihydroxy-olean-12- en-28-oic acid), which is abundant in olive 
has attracted much attention due to anti-tumor, anti-HIV, anti-oxidation and hypoglycemic 
properties. This pentacyclic triterpene has been shown to reduce high diet fat induced diabetic-
induced hyperglycaemia and hyperinsulinaemia in vivo (Liu et al., 2014). 
Triterpenes such as MA are generally hydrophobic and therefore are difficult to dissolve in water 
before administration. According to Williams et al. poor water solubility is a significant risk factor 
in low oral absorption because drug molecules must completely dissolve in water before oral 
administration (Williams et al., 2013). Therefore, medicinal chemistry seeks to modify 
physicochemical properties of different drugs to enhance their solubility. This study also focused 
on improving efficacy of MA by synthesizing a series of derivatives which would more soluble in 
water compared to the parent compound. Research indicates that synthesized or semi-synthesized 
drugs can have toxic effects on the cells. We also investigated the effects of synthesized derivatives 
on cell viability of kidney and liver cell lines. The following section describes synthesis of these 
triterpene derivatives based on their active sites.   
 
1.7 Triterpene derivatives  
Synthesis of triterpene derivatives was performed based on the currently known MA active sites. 
The first active site is the carboxylic group which has previously been shown to be responsible for 
glycogen phosphorylase (GP) inhibition (Wen et al., 2006). The second active site is C2-C3 which 
has previously been shown to inhibit expression of protein tyrosine phosphatase 1 (PTP1) (Li et 
al., 2004). The following section describes how inhibition of these enzymes may provide 






1.7.1 Active site I: glycogen phosphorylase (GP) inhibition  
Glycogen phosphorylase catalyzes the breakdown of glycogen to glucose-1-phosphate in liver and 
tissues leading to increased glucose in diabetics. Inhibition of hepatic GP is a promising treatment 
strategy for attenuating hyperglycaemia in diabetes mellitus. Glycogen phosphorylase inhibitors 
(GPis) have been shown to reduce liver GP activity and to dramatically attenuate hyperglycaemia 
without producing hypoglycaemia (Ogawa et al., 2003). These inhibitors have also been shown to 
be more potent in reducing hepatic glucose output in the presence of high glucose concentrations. 
MA is a natural GPi, the rate-limiting enzyme of glycogen degradation, and has therefore, been 
regarded as a promising therapeutic approach for diabetes mellitus and related complications. The 
carboxylic group shown in structure (Figure 2)  has been identified as the active site for GP (Fi) 
(Wen et al., 2006). Several derivatives have been synthesized with an effort to improve water 
solubility of this triterpene, as they are well known to have poor water solubility . The results were, 
however, disappointing as incorporation of hydrophilic groups on carbon 28 significantly 
decreased potency. According to Wen et al. introduction of hydrophobic groups (bromobutane) on 
carbon 28, carboxylic groups gives rise to a 7- fold increase effects compared to lead MA. 
Accordingly we opted to incorporate hydrophobic groups on c-28 to increase potency of MA. 
Reports indicate that MA uses two currently known active sites to mediate biological effects. The 

























Figure 2: Synthesis of maslinic acid derivative through addition of bromobutane and bromohexane 
on the carboxylic group. 
 
1.7.2 Active site II: Protein tyrosine phosphatase inhibition  
Discovery of clinically available PTP1B inhibitors has been difficult as they exhibit lack in 
selectivity. In recent years, there has been a growing interest in anti-diabetic agents from natural 
products. They represent an alternative mode for therapy as most of the anti-diabetic drugs have 
some side effects and fail to significantly alter the course of the disease. However, natural PTP1B 
inhibitors such as UA, OA and MA have been identified and demonstrated to possess blood 
glucose lowering effects (Na et al., 2006; Qiu et al., 2009). Indeed, we have observed that 
triterpenes such as OA do not only lower blood glucose but also improve kidney function in STZ-
induced diabetic rats a long term complication for diabetes mellitus. In searching for novel types 
of PTP1B agonists, researchers have found that pentacyclic triterpenoids such as OA to be 
moderate PTP1B inhibition (Zhang et al., 2006). Based on these results, some potent inhibitors 
with good cell permeability were obtained by modifying long hydrophobic chains at C-3 and C-
28 positions. However, these synthetic compounds had poor water solubility and had no obvious 
selectivity on PTP1B (Zhang et al., 2006; Zhang et al., 2008). MA has, however, been screened 
for PTP1B inhibition along with isomers such as 3-epi-maslinic acid and augustic acid on PTP1B. 
Among the MA isomers, MA demonstrated good PTP1B inhibition (IC50 = 5.93 µM). Hence our 
current research focuses on synthesizing MA derivatives with an aim to improve solubility; 
efficacy and bioavailability. To achieve this, a series of heterocyclic rings were incorporated in C-
2 and C-3 position based on the evidence that heterocyclic incorporating heterocyclic rings 
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improved efficacy of MA (Figure 2). The synthesis was based from previous studies which 
demonstrated the efficacy of MA derivatives after incorporating heterocyclic rings. To date no 
studies have been performed on these derivatives to investigate their effects on kidney function. 
Our goal was not only to manage blood glucose concentration, but to also evaluate whether MA 
























CH3 CH3  
Figure 3: Synthesis of tyrosine phosphatase inhibitor by insertion of phenyl hydrazine in carbon 
2 and 3.  
1.8 Methods to assess kidney function  
1.8.1 Lithium clearance  
A Perkin Elmer atomic absorption/flame emission spectrometer (Optima 2100 DV, New York, 
Waltham, USA) equipped with Li+ hollow-cathode lamp as a radiation source and air-nitrous 
oxide-acetylene flame with a wavelength of 670.8 nm has been used for determination of Li+ 
concentrations in plasma and urine samples. This is a controversial technique for proximal Na+ 
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handling as there is evidence that lithium can be reabsorbed by the distal nephron under certain 
conditions (e.g. Na+ and K+ depletion) (Shirley and Walter, 1997). However, since the animals 
used in the study were Na+ and K+ replete Li+ was assumed as a valid marker of proximal tubule 
function. Lithium (Li+) is, therefore, an ideal marker for proximal tubule function as this element 
is absorbed in the proximal tubule and does not induce any tubular secretions (Boer et al., 2005). 
In addition, Li+  is not actively transported in the proximal tubules, but is also transported at the 
same rate as Na+ and water (Holstey et al., 1985; Weder, 1986). Research indicates that most of 
the Li+ is reabsorbed in the proximal tubule at a range of 73 to 82% of the whole kidney.  Fractional 
excretion of lithium (FELi) in these rats has been reported to range from 25 to 35% (Shirley et al., 
2002).The proximal tubular reabsorption would, therefore, contain of 65-75 % of the filtrate. This 
evidence indicates that Li+ can, indeed be used to asses functioning of the proximal tubule in the 
kidney. Li+ clearance should, therefore, be used to assess the effects of anti-diabetic drugs, in this 
way it would be clear if they have any effects on renal electrolytes handling electrolytes handling.  
 
1.8.2 Cell culture studies  
Cell culture studies are important as they serve as a precursor to whole animal studies and help to 
determine whether significant cytotoxicity exists for the given material (Li et al., 2004). Culture 
of cell lines is essential for biomedical research which include medicine, vaccine development, 
genetics, HIV testing/treatment, reconstructive medicine, basic science, cell biology and drug 
discovery (Dunham and Guthmiller, 2008). Understanding the toxicity of drugs and chemicals is 
essential for progress in the pharmaceutical industry, medical science and academic research 
(Farkas and Tannenbaum, 2005).  A variety of cell viability study techniques are available and are 
used to screen drugs in pharmaceutical industries. However, current methods are relatively 
inconvenient, insensitive. These include direct cell counting by dye invasion, terminal 
deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assays (Fernandez and Sanchez, 
2001) and metabolism-based methods such as oxidation of MTT (Boncler et al., 2014). The LDH-
release method involves either direct measurement of LDH enzymatic activity by observing the 
reduction of NAD+ to NADH at 340 nm or indirect measurements of pyruvate depletion (Stewart 
et al., 1961). Neither method is highly sensitive both suffer from the possible presence of 
interfering substances in biological or cell-culture mixtures, and both are open to the objection that 
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many substances of biological interest contain moderate or large amounts of LDH. We, therefore 
opted to use CellTiter-Gloluminescent cell viability (ATP) assay due to its sensitivity and ability 
to give reproducible results. The ATP assay is considered the fastest cell viability assay to use, the 
most sensitive, and is less prone to artifacts than other viability assay methods. The luminescent 
signal reaches a steady state and stabilizes within 10 minutes after addition of reagent and glows 
with a half-life greater than 5 hours. The ATP assay has the advantage step with a population of 
viable cells to convert a substrate (such a tetrazolium or resazurin) into a colored compound. This 
also eliminates a plate handling step because you do not have to return cells to the incubator to 
generate signal (Riss et al., 2013). 
 
1.9 Basis of the study  
Despite the currently available commercial drugs for alleviating DN, morbidity of patients with 
DN is increasing. Alternative methods to ameliorate kidney function are needed. Clinical trials 
indicate that tight glycaemic control may prevent or delay the onset of DN. This study, therefore, 
focused on using MA and related derivatives on kidney function of STZ-diabetic rats. 
1.9.1 Objectives   
The objectives were to investigate the effects of MA and MA triterpene derivatives on renal Na+ 












MATERIALS AND METHODS 
2.  Drugs and chemicals  
Drugs were obtained from different sources as indicted: Sodium chloride (NaCl), metformin (1, 1-
dimethylbiguanide hydrochloride), streptozotocin, dimethyl suphoxide (DMSO), sodium citrate 
(Na3C6H5O7), lithium choride (LiCl), inactin (5-ethyl-5(1-methylpropyl)-2-thiobarbiturate), 
halothane (2-Bromo-2-Chloro-1, 1, 1-trifluoroethane) (Sigma St Louis, MO, USA);  
 
Ethyl acetate (EtOAc), silica gel, dichloromethane (DCM), ethanol (C2H5OH), methanol 
(CH3OH), chloroform (CHCl3) (Merck, Waderville, South Africa);  
 
Phosphate buffered saline (PBS), Eagle’s Minimal Essential Medium (EMEM), L-glutamine, 
fungizone/penicillin/streptomycin and trypsin (Highveld Biological, Johannesburg, South Africa) 
and  
Isofor inhalation anaesthetic (Safeline Pharmaceuticals (PTY) LTD, Weltevreden Park, 
Rooderport, South Africa).  
 
All chemicals were of analytical grade. 
 
2.1.  Methods  
 
2.1.1  Extraction of OA and MA  
 
MA and OA (Figure 4) were isolated from Syzygium aromaticum [(Linnaeus) Merrill & Perry] 
[Myrtaceae] (cloves) flower buds using a standard protocol that has been validated in our 
laboratory with minor changes (Mapanga et al., 2009; Madlala et al., 2012) . Briefly, air-dried S. 
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aromaticum flower buds (500 g) were sequentially extracted twice at 24 h intervals at room 
temperature with 1 L dichloromethane (DCM), and ethyl acetate (720 ml) on each occasion. 
Removal of the solvent from the extract under reduced pressure at 55±1°C using a rotary 
evaporator yielded dichloromethane solubles (DCMS, 63 g) and ethyl acetate solubles (EAS, 85 
g). The EAS containing mixtures of oleanolic/ursolic acid and methyl maslinate/methyl corosolate 
were purified by silica gel 60 column chromatography with a hexane: ethyl acetate 9:1, 8:2 solvent 
system increasing polarity. This yielded OA.  The polarity was then increased to 6:4 to obtain MA. 
The resulting white powder was recrystallized from chloroform-methanol (1:1, v/v). The structure 
of MA was confirmed by spectroscopic analysis using 1H and 13C nuclear magnetic resonance 
(NMR) techniques. The total of 10.5 g MA was obtained.  
                 MASLINIC ACID                                              OLEANOLIC ACID                        
 















CH3 CH3  
        
Figure 4: Chemical structure of maslinic acid (MA) and oleanolic acid (OA).  
 
2.2 Synthesis of MA derivatives 
2.2.1 Glycogen phosphorylase inhibition 
 
2.2.1.1 Substitution with bromobutane  
 
Reaction of MA (1.0 g, 2.1 mmol) with 1,4 bromobutane (1.1 g, 6.3 mmol) in the presence of 
potassium carbonate (0.029g, 2.1 mmol) in dimethylformamide [DMF (10 mL)] at room 
temperature resulted in formation of bromobutane derivative (Figure 4) . After 12 hours, the 
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reaction was diluted with H2O and bromobutane derivative was extracted with ethyl acetate. 
Column chromatography over silica gel hexane ethyl acetate and elution with 7:3 afforded pure 
bromobutane derivative which was recrystallized from methanol and chloroform affording 72% 
yield.   








Figure 5: Chemical structure of bromobutane substituted derivative.   
 
2.2.1.2 Substitution with bromohexane  
Reaction of MA (1.0 g, 2.1 mmol) with 1,6 bromohexane (1.5 g, 6.3 mmol) in the presence of 
potassium carbonate (0.029 g, 2.1 mmol) in dimethylformamide [DMF (10 ml)] at room 
temperature resulted in formation of bromohexane derivative (Figure 5). After 12 hours, the 
reaction was diluted with H2O (25 mL) and bromohexane derivative was extracted with ethyl 
acetate (60 x 3). Column chromatography over silica gel hexane ethyl acetate and elution with 7:3 
















Figure 6: Chemical structure of bromohexane substituted derivative   
 
2.2.2 Tryrosine phoshorylase (PTP1B) inhibition  
2.2.2.1 Oxidation of oleanolic acid  
 
Oxidation of OA was performed according a methods described by Zhang et al.(Zhang et al., 
2006). A suspension of oleanolic acid  (1.0 g, 2.2 mmol) in 10 mL CH2CL2/C3H6O (1/1) was 
cooled at 5 ˚C and a solution of Jones reagent (1.2 mL, 5 equiv) was added dropwise over 30 min 
and the reaction was allowed to run for 1 hour until the colour changed dark brown. Isopropanol 
and H2O (mL) were added to the reaction mixture. The reaction mixture was then stirred at room 
temperature for 15 minutes. H2O and CH2CL2 were added to the mixture and the layers were 
separated. The organic phase was washed with brine and concentrated to give 0.90 g of oxidized 
oleanolic acid (Figure 6). Pure product of oxidized OA was obtained by silica gel chromatography 

















Figure 7: Chemical structure of oxidised oleanolic acid.  
2.2.2.2 Phenyl hydrazine  
 Fischer indole synthesis was done according to a method described by Alonso et al. (Alonso et 
al., 2004). Briefly, a mixture of ketone (1 g, 2.2 mmol), phenylhydrazine (0.8 mL 0.9 mmol) and 
glacial acetic acid (5 mL) was heated at reflux under N2 for 1 h. During this period the colour 
changed from colourless to bright yellow. The reaction mixture was pipetted into distilled water 
(50 mL) and extracted with ether (4 x 20 mL). The combined ether extracts were washed with 5% 
aqueous NaOH (2 x 20 mL) and brine (2 x 20 mL), dried (Na2SO4), and concentrated in vacuo to 
give a yellow solid product. Chromatography over silica gel and elution with hexane: ethyl (7:3) 






















CH3 CH3   
Figure 8: Chemical structure of phenylhydrazine (PH) substituted derivative  
 
2.2.2.3 3-chloro phenyl hydrazine  
In similar manner as section 2.2.2.2 a ketone (1.0 g, 2.2 mmol) was mixed with 3-chloro phenyl-
hydrazine hydrochloric acid (1.6 g 8.8 mmol) in acetic acid (5 mL) heated at reflux under N2 for 1 























Figure 9: Chemical structure of chloro phenyl hydrazine (CPH) substituted derivative 
 
2.2.2.4 3-Flouro phenyl hydrazine  
Fischer indole synthesis was done according to a method described by Alonso at al. (Alonso et al., 
2004). Briefly, a mixture of oxidised OA (1 g, 2.2 mmol), 3-fluorophenylhydrazine hydrochloride 
(0.8 mL, 0.9 mmoL ) and glacial acetic acid (5 mL) was heated at reflux under N2 for 1 h. During 
this period the colour changed from colourless to bright yellow. The reaction mixture was pipetted 
into distilled water (50 mL) and extracted with ether (4 x 20 mL). The combined ether extracts 
were washed with 5% aqueous NaOH (2 x 20 mL) and brine (2 x 20 mL). These extracts were 
then dried in (Na2SO4), and concentrated in vacuo to give a yellow solid product (Figure 10). 
Chromatography over silica gel and elution with hexane: ethyl (7:3) acetate afforded an indole 






















Figure 10: Chemical structure of 3-fluorophenylhydrazine hydrochloride derivative 
 
2.3 Animal experiments  
2.3.1  Animals  
Male Sprague-Dawley rats weighing 250-300 g were obtained from Biomedical Research Unit 
(BRU), University of KwaZulu-Natal Westville campus. The animals were kept under maintained 
laboratory conditions of constant temperature (22±1 ˚C); C02  (<5000 p.p.m,), humidity of 55±5% 
and illumination (12 h light/dark cycles). The animals had full exposure to food standard rat chow 
(Meadows Feeds, Pietermaritzburg, South Africa) and water ad libitum.  
 
2.3.2 Ethical consideration 
The experiments and treatments of animals were performed according to University of KwaZulu-
Natal ethics committee guidelines for experimental animals. The ethical clearance was obtained 
from the animal ethics committee of the University of KwaZulu-Natal (UKZN) (002/13/Animal 




2.3.3  Induction of experimental diabetes 
Diabetes was induced with a single intraperitoneal injection of STZ (60 mg/kg) dissolved in 0.1 
M citrate buffer pH 6.3 (Musabayane et al., 2005; Hadebe et al., 2014). Control animals were 
injected with a vehicle, citrate buffer. Animals showing glucosuria after 24 h, tested by urine strips 
(Rapidmed Diagnostics, Sandton, South Africa) were considered diabetic. Blood glucose 
concentration of 20 mmol/L measured after one week was considered as stable diabetic state and 
these animals were used for carrying out the study.  
 
2.4 Experimental design  
Non-diabetic and STZ-induced diabetic rats were divided into separate groups to study the 
following: (1) acute effects of MA and derivatives on proximal tubule function (2) sub-chronic (5 
weeks) effects of MA on  blood glucose, kidney function and oxidative stress in livers, hearts and 
kidneys, (n=6 in each group). MDBK and Chang cells were divided into control and treated groups 








Figure 11: Experimental design for proximal tubular function, animals were treated with 3 MA 
derivatives for 1.5 h treatment period for acute studies. Subchronic, rats were treated with various 
doses of MA for a period of five weeks, organs, kidney, liver and heart were harvested and further 
used for biochemical analysis. Cell culture studies, where cells were treated with various doses of 
MA for 12, 24 and 48 h period.  
  
2.5 Cell viability 
2.5.1 Cell culture 
The Chang cell lines were kindly donated by Dr Christo J.F. Muller from the Diabetes Discovery 
Platform at the South African Medical Research Council (MRC), Cape Town, South Africa. Cell 
culture was conducted using a well-established cell culture protocol (Czifra et al., 2006) . Briefly, 
the reconstituted muscle and liver cell lines were plated in 25 cm3 flasks followed by addition of 
10 mL fully supplemented EMEM media, respectively. Thereafter, the flasks were incubated at 37 
ºC in a humidified incubator (Shel Lab, Cornelius, Oregon, USA) with 5% CO2. The cells were 
allowed to grow, attach and become confluent. The attached confluent cells were trypsinized with 
trypsin (1 mL) after washing three times with PBS. The trypsinized cells were sub-cultured into 
new flasks and some were stored in a nalgene cooler (Sigma-Aldrich, St Louis, Missouri, USA) at 




Chang and MDBK cell lines were divided into control and treated groups. Cell viability effects of 
MA and phenylhydrazine derivative were then evaluated on these cell lines. The effects of MA 
and PH derivative were investigated on cell viability and glucose utilization. Kidney (MDBK) and 
liver (Chang) cells were seeded in a 24 well plate at a density of (1.5 x 105 cells/mL). Both cell 
lines were allowed to attach and reach 80% confluent monolayer over 2 days. Each cell line was 
divided as follows: group 1 remained untreated and served as the control, group 2 was treated with 
MA and phenyl hydrazine derivatives at various doses (40, 80 and 160 µmol/L) and group 3 was 
treated with metformin (50 µmol/L).  
 
2.5.3 Effects of MA 
 
Cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, 
Madison, Wisconsin, USA). The assay reagent produces luminescence in the presence of 
adenosine triphosphate (ATP) from viable cells. The luminescence produced is proportional to the 
amount of ATP produced by viable cells. Both kidney and liver cells (10, 000 cells/mL) were 
seeded in 96- well plates and incubated in their respective media (200 μL) overnight. Thereafter, 
the cells were treated with MA or derivative (40, 80, and 160 μmol/L) some wells remained 
untreated, serving as a control. After every 12, 24 and 48 hours, plates were equilibrated at room 
temperature for 30 minutes. The assay reagent (100 μL) was added to each well, followed by 
shaking the plates for 2 minutes to induce cell lysis. After shaking, plates were incubated at room 
temperature for 10 minutes to stabilize the luminescence signal; thereafter the luminescence was 
read on the Promega Microplate Luminometer (Promega, Madison, Wisconsin, USA). All plates 
had wells media without cells, serving as a blank for background correction. Data were expressed 









2.5.4 Glucose utilization  
Glucose utilization was performed to investigate whether our triterpenes exhibited glucose 
lowering effects in Chang and MDBK cells. The glucose utilization experiments were performed 
as previously described Favaro et al. (Favaro et al., 2012) with slight modifications. MA or 
phenylhydrazine derivative (40, 80 and 160 µmol/L) and metformin (50 µmol/L) were introduced 
on separate wells in the 24 well plates containing cells. The 24 well plates were then incubated at 
37 ºC in a humidified incubator with 5% CO2. Glucose concentrations were measured after 12, 24, 
and 48 h hours using the OneTouch select glucometer (Lifescan, Mosta, Malta, and United 
Kingdom). After 48 h experimental period, cells were harvested for further biochemical analysis. 
At the end of the experiment, cells and media were stored at -70 for further analysis.  
 
2.5.6 ENaC  
 
To investigate the effects of PH and derivative on expression of ENaC, harvested MDBK cells 
(section 2.5.4) were used.  Cells (1 ml) were sonicated on ice in isolation buffer (0.5mM 
Na2EDTA, 0.1 M KH2PO4, 0.1mM dithiothreitol, 0.25M sucrose) and then centrifuged at 400xg 
for 10 minutes (4oC). The protein content was quantified using the Lowry method and all the 
samples were standardized to one concentration (1mg/mL). SDS-PAGE gel electrophoresis was 
performed as described in section 2.7.4, except that the PDVD membrane was immuno-probed 
with monoclonal anti-ENaC (1:1 000 in 1% BSA, Neogen, USA) for 1 h at room temperature 
(RT). 
 
2.6 Acute studies 
2.6.1 Proximal tubular function 
Sodium (Na+) reabsorption in the proximal tubule and, by implication, in the distal nephron was 
assessed through measurement of lithium clearance (CLi) (Thomsen and Shirley, 1997). The effects 
of MA and related triterpenes on MAP and renal function were investigated in separate groups 
anaesthetized of non-diabetic and STZ-induced diabetic male rats (Tecniplats, Labotec, South 
Africa) (n = 6 in each group). 48 h prior to experimentation the rats were fed standard rodent chow 
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supplemented with lithium chloride (12 mmol/kg dry weight) in order to raise plasma lithium to 
measurable concentrations without affecting renal sodium or water excretion (Shalmi and 
Thomsen, 1989) . Subsequently, renal clearance studies were conducted in inactin-anaesthetized 
(0.11 g/ kg) hypotonic saline infused non-diabetic and STZ-induced rats, a model which has been 
extensively used our laboratory (Madlala et al., 2012). Briefly, the right jugular vein was cannulated 
to allow a continuous intravenous infusion of hypotonic saline (0.077M NaCl) at 9 mL/ h  (Harvard 
syringe infusion Pump 22, Harvard Apparatus, Holliston, Massachusetts, USA). A catheter was 
inserted into the left carotid artery for withdrawal of blood samples and to record mean arterial 
blood pressure at 30 min intervals via a pressure transducer (Statham MLT 0380, Ad Instruments, 
Bella Vista NSW, Australia), compatible with PowerLab System ML410/W (Bella Vista NSW, 
Australia). The urinary bladder was also cannulated via an incision in the lower abdomen for the 
collection of urine samples. Animals were given a priming dose of creatinine (3 µg in 0.3 mL 0.077 
M NaCl) and then placed on a continuous infusion of 0.077 M NaCl containing creatinine (0.15 
µg/ml) of at 9 mL/h to allow calculation of creatinine clearance as a measure of GFR.  After a 3.5 
h equilibration period, blood samples (200 μL) were drawn at 1 h intervals and urine collections were 
made every 30 min over 4 h of 1 h control, 1.5 h treatment and 1.5 h recovery periods for 
measurement of electrolyte and clearance marker concentrations. In those animals in which the 
effects of MA and 3 MA derivatives were examined, the infusate was changed during the 1.5 h 
treatment period to one identical in ionic composition, but containing MA (90 µg/ h) and 22.5 µg/h 
of 3 MA derivatives. 
 
2.7. Sub-chronic effects on kidney function  
Non-diabetic and STZ-induced diabetic male Sprague-Dawley rats were divided into treated and 
untreated groups. MA (20, 40 and 80 mg/kg) was administered to non-diabetic and STZ-induced 
diabetic rats twice every third day at 9h00 and 15h00 for 5 weeks by means of ball-tipped, 18 
gauge gavage needle (Kyron Laboratories (Pty) LTD, Benrose, South Africa). The control and 
positive control animals received deionised water (0.3 mL/kg, p.o.) and metformin (500 mg/kg, 
p.o.), respectively. These were kept individually in Makrolonpolycarbonate metabolic cages 
(Techniplats, Labotec, South Africa) at the Biomedical Research Unit, University of KwaZulu-
Natal). Blood glucose concentration was measured after 6 hours of treatment using Bayer’s 
glucometer Elite (Elite Pty Ltd. Health care division, South Africa). Bodyweight changes, urine 
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output, food and water intake were measured after 24 h of MA administration ever third day.  Urine 
samples were collected for further analysis of renal function.  
 
2.7.1 Sub-chronic effects of MA on mean arterial pressure (MAP)  
MAP was monitored every third day at 09h00 by in conscious male Sprague Dawley rats for five 
weeks using non-invasive tail cuff method (IITC Model 31 Computerised Blood Pressure Monitor, 
Life Sciences, Woodland Hills, CA) previously described by Musabayane et al. (Musabayane et 
al., 2005) . The system uses a sensitive photoelectric sensor measurement of blood pressure pulses 
at a 37 ˚C. The results obtained from the sensors are displayed on the computer screen.  
 
2.7.2 Sub-chronic effects of MA on glucose homeostasis  
Non -diabetic and STZ-induced diabetic male Sprague-Dawley rats were divided into treated and 
untreated groups, standard rat chow (Meadows, Pietermaritzburg, South Africa) and water ad 
libitum was provided to the rats. MA (20, 40 and 80 mg/kg, p.o.) was administered to non-diabetic 
and STZ-induced diabetic rats twice every third day, at 9h00 and 15h00 for 5 weeks by means of 
bulbled steel tubes. The control and positive control animals received deionised water (0.3 ml/kg 
b.wt, p.o.) and metformin (500 mg/kg b.wt, p.o.), respectively. These were kept individually in 
Makrolonpolycarbonate metabolic cages (Techniplats, Labotec, South Africa) at the Biomedical 
Research Unit, University of KwaZulu-Natal). Blood glucose concentration was measured after 6 
hours of treatment using Bayer’s glucometer Elite® (Elite Pty Ltd. Health care division, South 
Africa) and parameters such as weight change, urine output, food and water intake were measured 









2.7.3 Analytical methods   
 
Urine flow was determined gravimetrically. Na+, K+, urea and creatinine were analysed using the 
Beckman Coulter Counter (Synchron CX3 Clinical Systems, Fullerton, California, USA) with 
commercial diagnostic kits from Beckman Coulter, Dublin Ireland. Lithium was determined flame 
emission spectroscopy at 670.8 nm (Optima 2100 DV, Perkin Elmer, Shelton, Connecticut, USA) 
using a modified procedure that has been previously described by Madlala et al. (Madlala et al., 
2012). Fractional excretions (FE) rates of Na+ (FeNa) and Li (FeLi) were determined 
simultaneously. Lithium clearance (CLi) was used as a marker for the output of Na
+ from the 
proximal tubules (Thomsen, 1990) . Renal clearances (C) and fractional excretions (FE) were 
calculated with the standard formulae C = U x V/P and FE = C/GFR, where U is the urinary 
concentration, V is the urine flow rate and P is the plasma concentration. Glomerular filtration rate 
(GFR), as assessed by creatinine clearance was calculated at 1 h intervals in anaesthetized rats and 
in the 5th week in conscious animals using the standard formulae from measurements of the plasma 
and urinary concentrations of creatinine and urine flow rate. 
 
2.7.4 Terminal studies  
At the end of the 5 week experimental period, all animals were sacrificed by exposing to halothane 
for 3 min via a gas anaesthetic chamber (100 mg/kg). Thereafter, livers, hearts, kidneys and 
gastrocnemius muscles were removed, snap frozen in liquid nitrogen and stored in a BioUltra 
freezer (Snijers Scientific, Tilburg, Netherlands) at -70 °C until use. Blood was collected from all 
rats by cardiac puncture into individual pre-cooled heparinized containers at the end of the 5-week 
experimental period and centrifuged using an eppendorf centrifuge 5403, Mazian Med Equip, 
Germany for 15 min at 3500 rpm G x 100 at 4 °C to separate the plasma. Plasma was frozen in a 
Bio Ultra freezer (Snijers Scientific, Holland, -80 °C) until used for different assays. Assays 







2.7.5. Biochemical measurements  
 
2.7.5.1 Evaluation of oxidative stress 
To establish the effects of MA on oxidative stress in the liver, heart and kidney of STZ-induced 
diabetic rats, we compared levels MDA, a commonly known marker of oxidative stress and of 
antioxidant defense enzymes SOD and GPx between non-diabetic control rats and MA-treated 
diabetic animals. All organs were analyzed for protein content in addition to other biochemical 
parameters. The protein content was quantified using the Lowry method (Lowry et al., 1951)  with 
2mg/mL BSA as standard (0-1mg/mL). Kidney, liver and heart samples (0.5 g) homogenized using 
isolation buffer (1 mL).  The homogenate (0.2 mL) was made up to 0.5 mL using distilled water 
and 5 ml alkaline reagent was then added and the mixture incubated for 15 min at 40 ̊ C.  After 15 
min 0.5 mL of Folin Ciocalteu reagent (diluted 0.5 with deionized water) was added. The 
absorbances were read at 600 nm after standing for 30 min. An alkaline reagent consisted of 100 
volumes of 4% sodium carbonate, 1 volume of 4% coppers sulphate and 4% of sodium potassium 
tartrate. A calibration curve was set up using BSA standards.  
 
2.7.5.2 MDA   
 
Tissues (50 mg) were homogenised in 500µl of 0.2% phosphoric acid. The homogenate was 
centrifuged at 400 x G for 10 minutes. Thereafter, 400 L of the homogenate was supplemented 
with 400L 2% phosphoric acid and then separated into two glass tubes, each receiving equal 
volumes of the solution. Subsequently, 200 µL of 7% phosphoric acid was added into both glass 
tubes followed by the addition of 400 µL of thiobarbaturic acid (TBA)/butylated hydroxytoluene 
(BHT) into one glass tube (sample test) and 400µL of 3mM hydrochloric acid (HCl) into the 
second glass tube (blank). To ensure an acidic pH of 1.5, 200 µL of 1M HCl was added to sample 
and blank test tubes. Both solutions were heated at 100oC for 15 minutes, and allowed to cool to 
room temperature. Butanol (1.5 mL) was added to the cooled solution; the sample was vortexed 
for 1 minute to ensure rigorous mixing and allowed to settle until 2 phases could be distinguished. 
The butanol phase (top layer) was transferred to eppendorf tubes and centrifuged at 13200xg for 6 
minutes. The samples were aliquoted into a 96-well microtitre plate in triplicate and the absorbance 
was read at 532nm (reference λ 600nm) on a BioTek Quant spectrophotometer (Biotek 
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Johannesburg, South Africa). The absorbances from these wavelengths were used to calculate the 
concentration of MDA using Beer’s Law. 
 
[𝑀𝐷𝐴] (𝑛𝑚𝑜𝑙 𝑔−1) =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒
𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (156 𝑚𝑀−1)
 
 
2.7.5.3 SOD  
 
SOD activity was assessed by measuring the dismutation of superoxide radicals generated by 
xanthine oxidase and hypoxanthine in a convenient 96 well format.  SOD activity was measured 
using the Biovision SOD Assay Kit according to manufacturers’ instructions (BioVision Research 
Products, Mountain View, California, USA). Rat liver, kidney and heart tissues (50mg) were 
homogenized in ice cold 0.1M Tris /HCl (pH 7.4) containing 0.5% Triton X-100, 5mM β- 
mercaptoethanol (ME) and 0.1mg mL-1 phenylmethanesulfonylfluoride (PMSF). The tissue 
homogenate was centrifuged at 14000 x G for 5 minutes at 4ºC. The supernatant obtained was 
added to each sample (20µL) and blank 2 (20 µL) well, while blank 1 and blank 3 wells received 
20 µl of H2O. Thereafter, 200 µL of working solution was added to each well. Subsequently, 
dilution buffer (20 µL) was added to each blank 2 and blank 3 well, while each sample and blank 
1 well received enzyme working solution (20 µL). The solutions were mixed thoroughly before 
reading the plate. Inhibition activity of SOD was measured on Anthos Venytch-200 
Spectrophotometer (Biochrom limited, Cambridge, United Kingdom) after a reaction period of 20 
minutes at 37 ºC.  
𝑆𝑂𝐷 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1 𝑚𝐿−1) =  
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)  −  (𝐴 𝑠𝑎𝑚𝑝𝑙𝑒 1 −  𝐴 𝑏𝑙𝑎𝑛𝑘 2)
(𝐴 𝑏𝑙𝑎𝑛𝑘 1 − 𝐴 𝑏𝑙𝑎𝑛𝑘 3)
 × 100 
                  
2.7.5.4 GPx  
 
Glutathione peroxidase (GPx) is an antioxidant enzyme which reduces liquid hydroperoxides to 
their corresponding alcohols and hydrogen peroxide to water through the oxidation of reduced 
glutatione (GSH) to oxidized glutathione (GSSG). GPx activity was measured in rat liver, kidney 
and heart tissues using the Biovision GPx Assay Kit according to manufacturers’ instructions 
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(BioVision Research Products, Mountain View, USA). The tissues (50 mg) were homogenized on 
ice in cold assay buffer (0.2 mL) and subsequently centrifuged at 10000 x G for 15minutes at 4oC. 
The resultant supernatant (100 µL) was loaded into a 96-well plate in duplicate. The NADPH 
standard curve was prepared by diluting the 1mM NADPH standard through a series of 
concentrations (0, 20,40,60,80, 100 nmol per well). The optical density of the standards (OD) was 
measured at 340nm using Anthos Venytch-200 Spectrophotometer (Biochrom limited, Cambridge, 
United Kingdom) and the standard curve was constructed from the values obtained. A reaction 
mix (90 µL) containing assay buffer, NADPH, glutathione reductase and GSH was added into 
each sample well, mixed thoroughly and incubated for 15 minutes at room temperature. The OD 
was then measured at 340 nm followed by the addition of cumene hydroperoxide (10 µL) and 
measurement of OD (T1) and another reading following a 5 minute incubation in the dark (25oC). 
GPx activity was calculated using following equation: GPx activity:  
 
𝑃𝑥 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝑛𝑚𝑜𝑙 𝑚𝑖𝑛−1𝑚𝐿−1) =  
(𝐵 − 𝐵0)
(𝑇2 −  𝑇1)  ×  𝑉
 × 𝑠𝑎𝑚𝑝𝑙𝑒 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 
 
Where: B - NADPH amount that was decreased between T1 and T2  
            B° - background change without cumene hydroperoxide between T1 and T2 
            T1 - time of first reading 
            T2 - time of second reading 
            V- pretreated sample volume added into the reaction well 
 
2.7.6 GLUT1, GLUT2 and GLUT4 
 
To evaluate the mechanism through which MA exerts its effects on blood glucose concentrations, 
expression of GLUT 1, 2 and 4 was investigated in kidney samples. Harvested organs from five 
week study were used to further elucidate mechanism through which MA exert blood glucose 
lowering effects. Kidney tissues were analyzed for GLUT1 and GLUT2 content while GLUT 4 
was analysed in gastrocnemius muscles. The tissue (0.1g) was homogenized on ice in isolation 
buffer (0.5mM Na2EDTA, 0.1m KH2PO4, 0.1mM dithiothreitol, 0.25M sucrose) and then 
centrifuged at 400xG for 10 minutes (4oC). The protein content was quantified using the Lowry 
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method described above and all the samples were standardized to one concentration (1 mg/mL) 
for consistency. The proteins were then denatured by boiling in laemmli sample buffer (0.5M Tris-
HCl, glycerol, 10% sodium dodecyl sulphate (SDS), 2-mercaptoethanol, 1% bromophenol blue) 
for 5min. The denatured proteins were loaded (25µL) on prepared resolving (7%) and stacking 
(4%) polyacrylamide gels along with molecular weight marker (5µL). The gel was electrophoresed 
for 1 h in electrophorese at 150V for 1 h in electrode (running) buffer (tris base, glycine, SDS), 
pH 8.3. Following electrophoresis, the resolved proteins were electro-transferred to an equilibrated 
polyvinylidene difluoride (PVDF) / nitrocellulose membrane for one hour in transfer buffer 
(192mM glycine, 25mM tris, 10% methanol). After transfer, the membrane was blocked with 5% 
non-fat dry milk in Tris-buffered saline with 0.1% Tween 20 (TTBS) (20mM tris, 150mM NaCl, 
KCl, 0.05% Tween-20). The membrane was then immuno-probed with monoclonal anti-GLUT-
1/2 (1:1 000 in 1% BSA, Neogen, USA) for 1 h at room temperature (RT). The PVDF membrane 
was then subjected to 5 washes (10 minutes each with gentle agitation) with TTBS.  Following 
which, the membrane was incubated in horse radish peroxidase (HRP)-conjugated secondary 
antibody (rabbit anti-mouse 1:10 000; Bio-Rad) for 1 hour at RT. After further washing, antigen-
antibody complexes were detected by chemiluminescence using the Immune-star HRP substrate 
kit (Bio-Rad). Chemiluminescent signals were detected with the Chemi-doc XRS gel 
documentation system and analysed using the quantity one software (Bio-Rad, Johannesburg, 
South Africa). Band intensity analysis was conducted on the resultant bands. 
 
2.7.7  AVP assay 
 
A standard enzymatic method was used to determine plasma AVP concentrations. The assays were 
performed on an Arg8-Vasopressin ELISA Kit, using reagents purchased from the manufacturer 
(Abcam, Cambridge, Massachusetts, USA). The lower and upper limits of detection were 4 pmol/L 
- 923 pmol/L respectively. The intra assay analytical coefficient of variation ranged from 5.9 - 
10.6 % and the inter-assay coefficient variation from 6.0 - 8.5 %. The kit components included a 
96 well plate coated goat antibodies, vasopressin conjugate, vasopressin antibody, assay buffer, 
wash buffer concentrate, vasopressin standards, p-nitrophenyl phosphatesubstrate (pNpp) and a 
stop solution. The Arg8-Vasopressin ELISA Kit is a competitive immunoassay for the quantitative 
determination of vasopressin in samples. The assay uses a polyclonal antibody-vasopressin 
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conjugate to bind covalently in a competitive manner with vasopressin in unknown samples. 
During the incubation period AVP in the sample reacts with phosphatase-conjugate anti-
vasopressin antibodies and anti-vasopressin antibodies bound to the micro-titration well. The 
washing step removes unbound enzyme labelled antibody, leaving the bound conjugate which 
reacts with pNpp. This reaction is stopped by adding an acid to give a colorimetric endpoint that 
is read spectrophotometrically on a microplate reader (BMG Labtech GmbH, Ortenberg, 
Germany) at 405 nm. 
 
A volume of 100 µL of vasopressin standards (0.29, 0.58, 1.15, 2.30 and 4.6 pmol/L) was added 
into anti-vasopressin wells. Samples (100 µL) were then added to the remaining wells followed by 
50 µL vasopressin conjugate into all standard and sample wells. The plates were incubated at 4 ºC 
for 24 hrs. Following incubation, the reaction volume was emptied. 400 µL of wash buffer was 
added to all wells and aspirated. The process was repeated 3 times. After the final wash, the plates 
were inverted firmly against absorbent paper to remove all the liquid. 200 µL of substrate pNpp 
was added to all wells and incubated at 37 ºC for 1 h. The reaction was stopped by adding 50 μL 
of stop solution to all wells and mixing on the shaker for 5 minutes.  The absorbance was read at 
405 nm using a Spectrostar Nano microplate reader (BMG Labtech GmbH, Ortenberg, Germany). 
A standard curve was constructed from the absorbance values of the known concentrations of the 
standards using the spline regression curve in GraphPad Prism Instat Software (version 5.00). The 
respective AVP concentrations of the unknown samples were then extrapolated from the standard 
curve. 
 
2.7.8 Aldosterone assay 
 
The kit components included a 96 well plate coated with a polyclonal rabbit antibody, aldosterone 
conjugate, wash buffer concentrate, aldosterone standards, and a stop solution. The aldosterone 
ELISA kit is a solid phase enzyme-linked ELISA based on the principle of competitive binding. 
The microtiter wells are coated with a polyclonal rabbit antibody directed towards an antigenic 
site of the aldosterone molecule. Aldosterone in the sample competes with an aldosterone-
horseradish peroxide conjugate for binding to the coated antibody. After incubation the unbound 
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conjugate is washed off. After addition of the substrate solution, the intensity of the colour is 
inversely proportional to the concentration of aldosterone in the sample. 
 
The assay procedure was as follows, 50 μL of each standard (0.11, 0.22, 0.43, 0.86, 1.73, 3.46 and 
6.92 pmol/L), control and samples were dispensed into appropriate wells, 150 μL of the 
aldosterone conjugate was then added into each well followed by mixing for 10 minutes and then 
incubation for 1 h at room temperature. The contents of the wells were shaken out and rinsed with 
300 μL of wash buffer was added to all wells and aspirated. The process was repeated 3 times. 
After the final wash, the plates were inverted firmly against absorbent paper to remove all the 
liquid followed by incubation of 30 minutes at room temperature. The reaction was stopped by 
adding 100 μL of the stop solution to all well. The absorbance was read at 405 nm using a 
Spectrostar Nano microplate reader (BMG Labtech GmbH, Ortenberg, Germany). A standard 
curve was constructed from the absorbance values of the known concentrations of the standards 
using the spline regression curve in GraphPad Prism Instat Software (version 5.00). The respective 



















2.8 Statistical analysis   
 
All data were presented as means or standard deviation (SEM). Statistical comparisons in different 
groups were performed by using one way analysis of variances (ANOVA), followed by Tukey-
Kramer multiple comparison test. All statistical analysis were performed with Graph-pad InStat 
Software (version 5, GraphPad Software, San Diego, California USA). A value of p<0.05 was 

























3.1  Structure elucidation  
 
3.2  MA and OA 
 
The percentage yield of MA obtained from EAS (10 g) varied from 0.02 to 0.03%.  The  carbon 
signals at 68.8 ppm, 121.9 ppm and 143.7 ppm correspond to carbon-OH (C-2) and carbon-carbon 
double bond (C-12 and C-13), respectively.  
 
3.2.1 13C NMR of MA 
The data below depicts different carbon positioning for MA dissolved in deuterated methanol.13C 
NMR (400 MHz,CD3OD): 46.2 (C-1), 68.3 (C-2), 83.3 (C-3), 39.1 (C-4), 55.0 (C-5), 18.1 (C-6), 
32.7 (C-7), 39.0 (C-8), C-9 (47.4), C-10 (38.0), C-11 (23.2), C-12 (121.9), C-13 (143.7), C-14 
(41.6), C-15 (27.4), C-16 (23.0), C-17 (46.2), C-18 (41.0), C-19 (45.7), C-20 (30.4), C-21 (33.6), 
C-22 (32.3), C-23 (28.3), C-24 (16.6), C-25 (16.5), C-26 (16.4), C-27 (23.2), C-28 (178.5), (C-29) 
32.2, C-30 (23.2). For supporting information (see appendices). The purity of the plant-derived 
MA was approximately 98%.   
 
3.2.2 13C NMR of OA  
The data below depicts different carbon positioning for OA dissolved in deuterated methanol 
13C NMR (400 MHz, CDCl3): δ 183.5, 143.8, 122.8, 79.2, 55.4, 47.8, 46.7, 46.1, 41.8, 41.2, 
39.4, 38.9, 38.6, 37.3, 34.0, 33.2, 32.8, 32.6, 31.8, 28.3, 27.9, 27.3, 26.1, 23.6, 23.1, 22.9, 18.5, 
17.3, 15.7, 15.5 
 
3.3 MA derivatives 
 
3.3.1 1H NMR CDCl3 of Bromobutane derivative  
1H NMR data below depicts different proton positioning for MA dissolved in deuterated 
chloroform. δ, 0.71, 0.80, 0.88, 0.91, 0.96, 1.01, 1.1 (each 3H, s), 2.86 (1h, dd, J = 4.5), 2.97 (1H, 
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d, J = 9.7), 3.40 (2H, t, J = 6.7), 3.70 (1H, m), 4.05 (2H, t, J = 6.3), 5.27 (1H, t, J = 4.0). The 
percentage yield of this derivative was 50% after recrystallization from methanol and chloroform 
(1:1 v/v). 
 
3.3.2 1H NMR CDCl3 of Bromohexane derivative  
1H NMR data below depicts different proton positioning for bromohexane derivative dissolved in 
deuterated chloroform. δ, 0.71, 0.80, 0.88, 0.90, 0.96, 1.04, 1.11 (each 3H, s), 2.85 (1H, d, J = 
9.51), 3.39 (2H, t, J = 6.7), 3.67 (1H, m), 4.00 (2H, dd, J = 6.6), 5.26 (1H, t, J = 3.5).  Data indicated 
that (2H, t, J = 6.7), 3.67 (1H, m), 4.00 (2H, dd, J = 6.6), 5.26 (1H, t, J = 3.5) indicating that two 
more hydrogens were introduced hence verifying that this was indeed a bromohexane derivative. 
A yield of 50% was obtained after recrytallisation from methanol and chloroform (1:1 v/v) and 
pure compound was obtained as white needles 
 
3.3.3 Oxidised OA 
1H NMR data below depicts different proton positioning of oxidised OA dissolved in deuterated 
chloroform. 1HNMR CDCl3, δ 0.80, 0.88, 0.91, 1.01, 1.02, 1.06, 1.13, (each 3H, s). 1.2-2.0 (m, 
21), 2.30-2.38 (m, 21), 2.48-2.57 (m, 2), 5.28 (br, s 1). White needles were obtained after 
recrystallisation affording 100% yield. 1H NMR data was comparable to previously oxidized 
OA. 
 
3.3.4 1HNMR CDCl3 of Phenylhydrazine (PH-MA) derivative  
1H NMR data below depicts different proton positioning for phenylhydrazine (PH-MA) derivative 
dissolved in deuterated chloroform. 1HNMR CDCl3, δ 0.85. 0.90, 0.94, 1.16, 1.17, 1.24, 1.27 (each 
3H, s), 2.21 (IH, d, J = 14.5), 2.77 (1H,d, J = 14.7), 2.87 (1H, m, ), 5.28 (1H, s,), 7.05 (1H, m), 
7.10 (1H,m), 7.29 (1H, d, J = 7.8), 7.40 (1H, d,  J = 7.5), 7.69 (1H, s, NH). The total of 80% was 





3.3.5 1HNMR CDCl3 of chloro-phenyl hydrazine derivative  
1H NMR data below depicts different carbon positioning of choloro-phenylhydrazine (PH-MA) 
derivative dissolved in deuterated chloroform. 1HNMR CDCl3, δ 0.84, 0.92, 0.94, 1.16, 1.17, 1.24, 
1.27 (each 3H, s), 2.17 (1H, d, J = 1.44) 2.73 (1H, d, J = 14.79), 2.87 (1H, m), 5.37 (1H, m), 6.99 
(1H, m), 7.01 (IH, m), 7.29 (1H, d, J =8.45), 7.7 (1H, s), 8.0 (1H, s). The total of 75% yield was 
obtained for 3-phenyl-hydrazine derivative in a form of brown particles.   
 
3.3.6 1HNMR CDCl3 of 3- flouro-phenyl hydrazine  
1H NMR data below depicts different proton positioning for 3-flouro-phenylhydrazine (F-PH) 
derivative dissolved in deuterated chloroform. δ 0.85. 0.90, 0.94, 1.16, 1.17, 1.24, 1.27 (each 3H, 
s), 2.21 (IH, d, J = 14.5), 2.77 (1H,d, J = 14.7), 2.87 (1H, m, ), 5.28 (1H, s,), 7.05 (1H, m), 7.10 
(1H,m), 7.29 (1H, d, J = 7.8), 7.40 (1H, d,  J = 7.5), 7.69 (1H, s, NH). Yield (86%) as a yellow 
solid (3-flouro phenyl hydrazine derivative) was obtained from recystallisation. 
 
3.4 Cell viability studies  
 
3.4.1 Effect of MA on MDBK and Chang cells 
 
Figure 12 shows percentage viability of MDBK and Chang cell lines after treatment with either 
MA or PH-MA. The viability of all controls remained stable at 100 % from 12-48 h experimental 
period. All MA doses exerted no significant effects on cell viability of MDBK cells after 12 and 
24 h treatment (Figure 12 A). However, MA (80 µmol/L) significantly (p< 0.05) increased cell 
viability of MDBK cells after 48 h treatment by comparison with the control. Administration of 
MA (40 and 80 µmol/L) also exerted no significant effects on viability of Chang cells after 12 and 
24 h treatment period. However, the highest dose (160 µmol/L) significantly (p<0.05) increased 
cell viability by comparison with the control (Figure 13 B). Administration of PH-MA (40 and 80 
µmol/L) significantly increased viability of MBK cells after 12 h treatment, however, doses 80 
and 160 µmol/L significantly (p<0.05) decreased cell viability by MDBK cells by comparison with 
respective controls (Figure 13 A). All PH-MA doses significantly (p< 0.05) decreased cell viability 
of MDBK cells after 48 h treatment. However, PH-MA showed no significant changes in cell 




3.4.2 Effects of MA on glucose utilisation  
 
Glucose utilisation by MDBK and Chang was investigated following exposure of these cell lines 
to different concentrations of MA or PH-MA.  Results indicate that MA exerted no effects on 
glucose utilisation from 12 to 24 h treatment of MDBK cells. However, a significant (p<0.05) 
decrease in glucose utilisation at 48 h MA treatment (80 and 160 µmol/L) on MDBK cells (Figure 
14 A). In contrary, Chang cells showed no significant change on glucose utilisation following 
treatment with various doses of MA (Figure 14 B). PH administration showed no significant effects 
on glucose utilisation by MDBK cells (Figure 15 A). However, all PH-MA doses significantly 
increased glucose utilisation from 24-48 h treatment period. These results were comparable to that 
of metformin (Figure 15 B). 
 
3.4.3 Effects of MA and PH on ENaC expression   
 
Effects of MA and PH-MA on ENaC expression were evaluated using Western blot analysis. Cells 
were harvested after 48 h of treatment with MA. Cells treated with PH were harvested after 12 h 
since this triterpene showed deleterious effects on viability after 24 and 48 h. Harvested cells were 
then used to evaluate expression of these transporters. Results indicate that treatment with various 
doses of MA significantly (p<0.05) decreased expression of ENaC by comparison with the control 
(Figure 16). Administration of PH-MA significantly (p<0.05) decreased expression of ENaC by 

















































Figure 12: Viability of MDBK (A), and Chang (B) cell lines exposed to different doses of MA at 
12, 24 and 48 h time periods.  Values are presented as means, and vertical bars indicate SEM (n=6 













































Figure 13: Viability of MDBK (A) and Chang (B) cell lines exposed to different doses of PH-MA 
at 12, 24 and 48 h time periods. Values are presented as means, and vertical bars indicate SEM 

















































Figure 14: Effects of MA on glucose utilisation on MDBK (A) and Chang cells (B) following 
treatment at 12, 24 and 48 h. Cell lines were exposed to 19 mmol of glucose prior the experiment 
Values are presented as means, and vertical bars indicate SEM (n=6 in each group.    p<0.05 by 































































Figure 15: Effects of PH-MA on glucose utilisation on MDBK (A) and Chang (B) cells following 
treatment at 12, 24 and 48. Cell lines were exposed to 19 mmol of glucose prior the experiment. 
Values are presented as means, and vertical bars indicate SEM (n=6 in each group.    p<0.05 by 
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Figure 16: Effects of MA (A) and PH-MA (B) on expression of epithelial sodium channel γ-ENaC 
transport protein as determined by Western blotting. Groups were divided into control, MA, PH 





















3.5 Acute effects on kidney function 
 
3.5.1 Effects of MA on proximal tubular function  
 
The effects of MA and derivatives on proximal tubular function were investigated in anaesthetized 
non-diabetic and STZ-induced diabetic rats.  The animals were challenged with hypotonic saline 
after 3½ h equilibration for 4 h of 1 h control, 1½ h treatment and 1 ½ h recovery periods. Figure 
17 shows urine flow and urinary excretion rate of Na+, K+ and Cl- of control and MA treated 
animals. STZ-induced diabetic control rats exhibited lower urine flow and electrolyte excretion 
rates by comparison with non-diabetic rats. The urinary excretion Na+ of control non-diabetic 
animals ranged from 711 to 756 µmol/h throughout the 4 h post experimental period compared to 
the infusion rate of 693 µmol/h. Infusion of MA (90 µg/h) during 1½ h treatment significantly 
(p<0.05) increased Na+ excretion from the pre-treatment mean value of 650 to 818 µmol/h (Figure 
17, A). However, treatment with MA did not change urinary excretion of K+ and Cl- (Figure 17, 
B-C). Figure 17 E shows that the urinary excretion Na+ of untreated STZ-induced diabetic animals 
ranged from 290 to 313 µmol/h throughout the 4 h post experimental period. Infusion of MA (90 
µg/h) during 1½ h treatment significantly (p<0.05) increased Na+ excretion from the pre-treatment 
mean value of 304 to 431 µmol/h. MA, however, did not change urinary K+ and Cl- excretion rates 
by comparison with control animals (Figure 17, F-G).  
 
3.5.2 Effects of MA derivatives (PH-MA, F-PH and Cl-PH) on proximal tubular function  
 
The infusion of PH-MA at 22 µg/h significantly (p<0.05) increased Na+ excretion of non-diabetic 
and STZ-induced diabetic rats (696 to 1154 and 312 to 477 µmol/h, respectively) (Figure 18, A 
and E respectively). Infusion of F-PH and Cl-PH also significantly (p<0.05) increased Na+ 
excretion in non-diabetic rats, however, Cl-PH resulted in significant decrease in Na+ during 
recovery period (Figure 19, A and D). The Effects of Cl-PH and F-PH were only investigated in 
non-diabetic animals due to limited sample size. PH-MA, Cl-PH and F-PH did not change urine 





3.5.3 Cumulative data  
 
The mean total volume of urine and amounts of Na+ K+ and Cl- excreted in 1 h 50 min of the 
treatment period are presented in Table 2. STZ- diabetic rats treated with MA or PH showed a 
significantly low urinary Na+, K+ and Cl- by comparison with non-diabetic animals. However, PH 
(22 µg) was more effective in excreting urinary Na+ when compared to MA (90 µg) in non-diabetic 
animals. In all MA or PH -treated groups, the total urine, K+ and Cl- excretion outputs were not 
significantly altered by any of the treatments. 
 
3.5.4 Renal clearance  
 
The effects of MA on proximal tubular Na+ clearance were estimated by comparing renal lithium 
clearance (FELi
+) between anaesthetized non-diabetic, STZ-induced diabetic controls and MA-
treated rats. These effects were only investigated on animals treated with MA and PH since they 
were more effective than the other triterpenes. Infusion of MA (90 µg/h) for 1½ h significantly 
(p<0.05) increased fractional excretion rates of sodium (FENa+) and lithium (FELi+) in non-diabetic 
and STZ-induced diabetic rats by comparison with respective controls (Figure 20). Like MA, 
infusion of PH (22 µg/h) for 1½ h significantly (p<0.05) increased fractional excretion rates of 
sodium (FENa+) and lithium (FELi+) in non-diabetic and STZ-induced diabetic rats by comparison 
with respective controls (Figure 21). 
 
3.5.5 MAP and GFR  
 
The MAP of control non-diabetic and untreated STZ-induced diabetic animals did not show any 
significant variations throughout the 4 h post equilibration period. For purpose of this study acute 
effects on MAP were investigated on MA treated animals only. The MAP values in untreated 
diabetic rats (119 to 120 mmHg) were higher than that of control non-diabetic rats (104 to 105 
mmHg). However, MA administration significantly (p<0.05) decreased blood pressure in both 
groups of animals which persisted during 4 h post-treatment. Blood pressure decreased from 104 
to 91 mmHg and 119 to 98 mmHg for non-diabetic and STZ-induced diabetic rats respectively 
(Figure 22). Figure 23 shows that the GFR values of untreated diabetic rats (range 0.39-0.45 
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mL/100 g) were lower than that control non-diabetic rats (range 0.76-0.80 mL min/100 g). MA 
and PH-MA administration for 1.5 h significantly increased (0.39 to 0.60 and 0.39 to 0.65 
mL/min/100g respectively) GFR in STZ-induced diabetic rats. However, administration of PH-
MA or MA did not alter GFR in non-diabetic animals (Figure 23).  
 
3.6 Effects of MA on plasma hormones 
 
3.6.1 AVP and aldosterone  
 
Table 4 shows the concentration of plasma aldosterone and AVP measured in non-diabetic and 
STZ-diabetic rats following 1.5 h treatment period. Plasma AVP levels of untreated STZ-diabetic 
rats were significantly elevated (2.82 ± 0.47 to 4.45 ± 0.24 pmol/L) when compared to non-diabetic 
rats.  Administration of MA or PH-MA during 1.5 h of treatment showed no significant difference 
in AVP levels for both non-diabetic and STZ-diabetic rats. Like AVP, aldosterone levels of 
untreated STZ-induced diabetic rats were significantly elevated (0.78 ± 0.04 to 1.45 ± 0.03 nm/L) 
when compared to non-diabetic animals. Interestingly, MA and PH-MA significantly (p<0.05) 
decreased aldosterone levels of STZ-induced diabetic rats when compared to the control group. 





































































































































































































Figure 17: Comparison of the acute effects of MA administration of on urinary excretion rates of 
Na+, K+ and Cl- and urinary output of non-diabetic rats (A–D) and STZ-induced diabetic rats (E–
H) with respective control animals. MA was infused at 90 µg/h for 1.5 h during the treatment 
period. Values are presented as means for each 30 min collection; vertical bars indicate SEM of 






























































































































































































Figure 18: Comparison of the acute effects of PH-MA administration of on urinary excretion rate 
of Na+, K+ and Cl- and urinary output of non-diabetic rats (A–D) and STZ-induced diabetic rats 
(E–H). PH was infused at 90 µg/h for 1.5 h during the treatment period. Values are presented as 
means for each 30 min collection; vertical bars indicate SEM of means (n=6 rats in each group).     






























































































































































Figure 19: Comparison of the acute effects of F-PH (A-C) and Cl-PH (D-F) administration on 
urine flow, Na+ and K+ excretion rate of non-diabetic rats. F-PH and Cl-PH were infused at 22 
µg/h for 1.5 h during the treatment period. Values are presented as means for each 30 min 
collection; vertical bars indicate SEM of means (n=6 rats in each group).     p<0.05 by comparison 






Table 2: Comparison of the effects MA and PH-MA in 1.5 h on the total amounts of urine voided 
and Na+, K+ and Cl- excreted during 1.5 h treatment of non-diabetic and STZ-induced diabetic rats 
with respective control groups. Data are expressed as mean ± SEM, n = 6 in each group.  
  
Group UV (mL)  Na+ (mmol) K+ (mmol) Cl- (mmol) 
Non- 
Diabetic 
MA 14.10±0.06  1.22±0.02 1.22±0.02 1.18±0.02 
PH-MA 14.55±0.06  1.94* ±0.02 1.08±0.02 1.20±0.02 
STZ-
Diabetic 
MA 13.50±0.06 0.24±0.08# 0.32±0.02 # 0.46±0.02# 
PH-MA 13.07±0.03 0.86* ±0.02# 0.31±0.01# 0.74±0.02# 
 
* p<0.05 by comparison with respective individual groups (e.g. non-diabetic MA and non-
diabetic PH-MA)  




























































































Figure 20: Effects of intravenously infused MA on FELi+ and FENa+ in non-diabetic (A-B) and 
STZ-induced diabetic (C-D) rats (n=6 in each group). Values are presented as means, and vertical 






















































































Figure 21: Effects of intravenously infused PH-MA on FENa+ and FELi+ in non-diabetic rats (A-
B) and STZ-induced diabetic (C-D) (n=6 in each group). Values are presented as means, and 



















































Figure 22: Effects of intravenously infused MA (1½ h) on MAP in non-diabetic rats. Values are 
presented as means, and vertical bars indicate SEM (n=6 in each group).    p<0.05 by comparison 
































































































Figure 23: Comparison of the acute effects of MA (A and C) and PH-MA (B and D) administration 
on GFR rate of non-diabetic and STZ-induced diabetic. MA or PH-MA was infused at 90 µg/h for 
1.5 h during the treatment period. Values are presented as means for each 30 min collection; 
















Table 3: Plasma hormone concentration in rats after MA or PH-MA administration for 90 min of 
treatment.  
 
Groups  AVP (pmol/L) Aldosterone (nm/L) 
Non-diabetic control 2.82 ± 0.47 0.78 ± 0.04 
Non-diabetic MA  treated 2.38 ± 0.21 0.70 ± 0.01 
Non-diabetic PH treated 2.44 ± 0.10 0.75 ± 0.07 
STZ-diabetic control 4.45 ± 0.24# 1.45 ± 0.03# 
STZ-diabetic MA treated 4.00 ± 0.26 0.79 ± 0.05* 
STZ-diabetic PH treated 4.42 ± 0.33 0.80 ± 0.07* 
 
* p<0.05 by comparison with respective control animals;  




































3.7 Sub-chronic  
   
3.7.1 MA effects on body weight, food and water intake  
 
Synthesis of derivatives afforded lower yields of derivatives, hence only MA was used to carry 
out the short-term studies. Table 4 shows the effects of MA on mean weekly food intake, water 
intake and body weight change in non-diabetic and STZ-induced diabetic rats measured 24 h after 
treatment over a 5-week study period. Untreated diabetic rats exhibited severe wasting despite the 
significantly higher weekly intake of food and water when compared with non-diabetic control 
rats.  In contrast, non-diabetic control animals progressively gained weight from the 2nd week until 
the end of the experimental period. Administration of various doses of MA (20, 40 and 80 mg/kg, 
p.o.) to STZ-induced diabetic rats, however, stabilised body weight from the 4th to the 5th week of 
the experimental period. Like-wise, reduction in body weight of STZ-induced diabetic rats was 
stabilised by metformin from the 3rd to the 4th week of the experimental period. Kidney weight 
was significantly increased in STZ-diabetic rats by comparison with non-diabetic animals. 
Administration of MA or metformin did not affect the kidney mass in non-diabetic and STZ-
diabetic rats (Table 5).  
 
3.7.2 Effect of MA on renal fluid and electrolyte handling 
 
The mean weekly urine volume was elevated in untreated STZ-induced diabetic by comparison 
with non-diabetic control animals throughout the 5-week experimental period. Administration of 
MA did not have significant effects on urine volume for both non-diabetic and STZ-induced 
diabetic animals (Figure 24). Urinary Na+, K+ and Cl- outputs of untreated STZ-induced diabetic 
rats were significantly lower than those of control non-diabetic animals throughout the 5–week 
period (Figure 24). However, administration of MA (40 mg/kg, p.o.) to non-diabetic rats 
significantly (p < 0.05) increased mean weekly urinary Na+ output from the 1st week value of 171 
to 277 mmol/L and the 80 mg/kg, p.o. dose increased urinary Na+ output from the 1st week value 
of 171 to 281 mmol/L without affecting weekly urinary K+ and Cl- outputs. Like in non-diabetic 
animals, MA (40 mg/kg, p.o.) significantly (p<0.05) increased urinary Na+ output of STZ-diabetic 
rats from the 1st week value of 22 to 27 mmol/L and MA (80 mg/kg, p.o.) increased weekly Na+ 
excretion from the 1st week value of 22 to 38 mmol/L at the end of the experiment without 
influencing the urine flow rate, urinary K+ and Cl- excretion rate. An increase in Na+ output by 
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MA was not reflected in plasma collected at the end of the experiment as there was no significant 
difference in non-diabetic control and treated animals (Table 5).  
 
At the end of 5-week experimental period, plasma creatinine concentrations were significantly 
(p<0.05) elevated in control STZ-induced diabetic rats by comparison with untreated non-diabetic 
rats (Table 5). Administration of MA (40 and 80 mg/kg, p.o.) significantly decreased plasma 
creatinine concentration of STZ-diabetic rats with a concomitant increase in GFR with no 
influence on GFR on non-diabetic rats.  
 
3.7.3 Effects of MA on MAP  
 
Figure 25 shows the effects of MA on MAP of non-diabetic and STZ-induced diabetic conscious 
rats during the 5 week study period. MAP of non-diabetic control animals was stable varying from 
99 to 100 mmHg throughout the 5-week experimental period. MAP of the untreated STZ-induced 
diabetic rats was significantly (p<0.05) elevated compared to non-diabetic control animals. 
Administration of MA (20 mg/kg, p.o.) did not have significant effects on MAP. However, 
administration of various doses of MA (40 and 80 mg/kg, p.o.) significantly (p<0.05) reduced 
MAP from the 3rd week until the end of the experiment by comparison with the control animals at 
corresponding time periods (Figure 25 A). Treatment of the STZ with MA (40 and 80 mg/kg, p.o.) 
significantly (p<0.05) reduced MAP from the 1st week value of 119 to 100 mm Hg (MA 40 mg/kg, 
p.o.) and from the 1st week value of 120 to 96 mmHg (MA 80 mg/kg, p.o.) at the end of the 
experimental period (Figure 25 B). 
 
3.7.4 GLUT 1 and 2 expression  
 
The effects of MA on the expression of glucose transporters was evaluated in glucose transporters 
expression, renal GLUT 1 and 2 were analysed using Western blotting in tissues harvested from 
non-diabetic and STZ-induced diabetic rats at the end of 5-week MA treatment. The GLUT1 and 
GLUT2 expression were significantly elevated in kidney tissues of untreated STZ-induced diabetic 
rats compared with control non-diabetic animals (Figure 26). In comparison with respective 
control groups, MA treatment not only abolished the diabetes- induced increase in GLUT1 and 
GLUT2 but also decreased the expression of these transporters in non-diabetic animals. 
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3.7.5 GLUT 4 expression   
 
Figure 27 shows the effects of MA on expression of GLUT4 in gastrocnemius of non-diabetic and 
STZ-induced diabetic rats. GLUT4 content in gastrocnemius muscle of diabetic rats was markedly 
lower as compared with non-diabetic control animals. MA did not have any significant effects on 
the expression of GLUT4 in the muscle of non-diabetic rats. Surprisingly, MA increased GLUT4 
content in diabetic rat skeletal muscle, but no effect of metformin was observed. Moreover, 
administration of MA (40 and 80 mg/kg p.o.) significantly (p<0.05) reduced glucose 
concentrations from the second week of treatment in STZ-induced diabetic rats by comparison 
with untreated STZ-induced diabetic rats. However, MA exerted no significant changes on blood 
glucose concentrations of non-diabetic animals (Figure 28).  
 
3.7.6 Oxidative stress 
 
The concentrations of MDA and antioxidants enzymes (SOD and GPx) in non-diabetic control 
animals represent baseline levels found in the tissues used (Table 6). Significant (p<0.05) increases 
of MDA and decreases of enzymatic oxidants, SOD and GPx were found in the liver heart and 
kidney tissues of diabetic group by comparison with controls to animals. Treatment of diabetic rats 
with MA significantly (p<0.05) reduced MDA levels in all tissues and decreased SOD activities 
of SOD and GPx in the liver and kidney compared to untreated diabetic group. On the other hand, 
GPx activity was undetectable (<0.01 nm/min/mL g protein) in the heart for all groups except for 












Table 4: Effects of MA on food and water intake, and body weight change with control animals 
during the 5-week study (n=6 in each group). Values are expressed as mean ± SEM. * p<0.05 by 
comparison with control animals.  
 
 Time (weeks) 








ND 10.0± 0.4 9.2 ± 0.4 10.0 ± 0.4 10.1 ± 0.4 11.0 ± 0.3 
STZ 50.0±0.4 50.0±1.0 49.1±1.1 50.0±1.0 48.2±1.2 
 
MA 20 
ND 10.0±0.4 11.1±0.2 10.3±0.4 11.4±0.4 10.2±0.4 
STZ 10.2±0.4 11.2±0.2 10.1±0.4 10.1±0.4 10.0±0.4 
 
MA 40 
ND 10.0±0.2 9.1±0.4 10.2±0.4 10.1±0.4 9.0±0.2 
STZ 11.1±0.4 11.0±0.4 12.0±0.2 12.0±0.4  13.0±0.6 
 
MA 80 
ND 10.1±0.2 11.1±0.4 11.1±0.2 10.0±0.4 11.1±0.4 
STZ 10.1±0.2 10.0±0.4 10.2±0.4 9.0±0.4 8.1±0.2 
 
Metformin 
ND 10.0±0.4 12.2±0.4 12.3±0.4 12.2±0.3 10.1±0.4 





(mL /100 g) 
 
Control 
ND 11.1±0.4 12.2±0.4 12.2±0.4 12.1±0.4 11.2±0.4 
STZ 48.1±0.4 49.2±2.2 48.2±1.1 50.1±1.4 50.0±1.6 
 
MA 20 
ND 11.5±0.4 10.3±0.2 13.2±0.2 12.2±0.4 11.1±0.4 
STZ 50.4±1.1 49.2±1.0 49.3±1.3 48.2±1.2 50.0±1.0 
 
MA 40 
ND 10.2±0.4 10.1±0.1 10.0±0.4 11.2±0.4 10.3±0.4 
STZ 47.1±0.4 48.2±1.0 50.1±1.0 50.2±1.0 50.1±1.4 
 
MA 80 
ND 10.2±0.2 11.3±0.2 11.4±0.4 11.±0.4 9.2±0.4 
STZ 49.1±1.8 48.2±2.6 48.2±2.2 46.1±3.5 45.7±2.0 
 
Metformin 
ND 9.1±0.2 10.0±0.4 11.0±0.4 10.0±0.2 11.0±0.4 










ND 7.0±1.1 6.1±2.0 8.2±1.3 13.1+1.2  22.0±1.0 
STZ 8.2±1.1 -1.0±1.1 -10.1±1.0 -2.5±1.1 -5.0±1.1 
 
MA 20 
ND 4.1±1.0 2.1±1.0 5.2±2.3 9.2±1.2 14.1±1.1 
STZ -1.3±0.1 -1.2±1.0 2.1±1.0 3.2±1.1 3.2±1.2 
 
MA 40 
ND 6.0±0.8 8.0±1.2 12.0±1.0 15.1±1.0 23.0±1.1 
STZ -1.0±0.2 -2.1±1.2 2.1±1.0 *8.2±1.0 *7.0±1.0 
 
MA 80 
ND 7.2±1.1 9.2±2.0 10.1±1.2 14.0±2.1 25.0±1.1 
STZ -1±2.2 -2.0±1.1 1.2±1.2 3.2±2.3 *4.2±1.3 
 
Metformin 
ND 8.0±2.0 7.2±1.0 12.1±2.1 16.±1.2 22.1±1.1 










Table 5: The effects of various MA doses in plasma biochemical parameters in non-diabetic 





* p<0.05 by comparison with respective control animals 
♦p<0.05 by comparison with respective non-diabetic animals  
 
Parameters  
Treatment              Na+ 











100 g)  
Kidney mass 
(g/100g) 
Control ND 139±1 4.8±0.3 105±1 6.7±1.3 26.0±1.1 1.0±0.1 0.5±0.1       
STZ 138±3 3.8±0.1 106±3 9.2±1.4 33.2±1.0♦ 0.3±0.1♦ 0.9±0.2♦ 
MA 20 ND 136±1               4.1±0.2 102±4 7.3±0.8 24.1±1.1 0.9±0.1 0.6±0.1 
STZ 137±2 4.2±0.2          108±2 8.9±1.1 26.2±1.0      0.2±0.1♦ 0.8±0.1♦ 
MA 40 ND 138±3 4.2±0.3 100±3 7.0±1.5 20.1±1.3* 0.8±0.1 0.6±0.1 
STZ 132±1 3.9±0.2 104±1 9.5±0.7 22.0±1.0* 0.6±0.1* 0.8±0.1♦ 
MA 80 ND 138±2 4.5±0.1 103±1 7.6±1.1 18.0±1.0* 0.9±0.1* 0.5±0.1 


















































































































































































Figure 24: Comparison of the effects of the administration of MA (80 mg kg, p.o.) twice daily on 
urinary excretion rate of Na+, K+  Cl- and urinary outputs in non-diabetic rats (A–D) and STZ-
induced diabetic rats (E–H) with respective control animals. Values are presented as means for 
each week; vertical bars indicate SEM of means (n= 6 rats in each group).      p<0.05 by comparison 





























































Figure 25: The effects of MA on 24h MAP of non-diabetic (A) and STZ-induced diabetic rats 
(B). Values are presented as means, and vertical bars indicate SEM (n=6 in each group).   p<0.05 












Figure 26: Effects of MA on expression of GLUT1and GLUT2 as determined by Western blotting 
of control, MA-treated and metformin-treated kidney tissues of non-diabetic and STZ-induced 
diabetic rats. Values are expressed as mean ±SEM,     p<0.05 by comparison with control animals 







Figure 27: Effects of MA on GLUT4 expression as determined by Western blotting of control, 
MA-treated and metformin-treated skeletal muscle tissues of non-diabetic and STZ-induced 
diabetic rats. Values are expressed as mean ± SEM. Values were obtained from Western blots for 
six preparation.     p<0.05 by comparison with control animals at each corresponding time,    p<0.05 
































































Figure 28: Effects of various doses of MA on blood glucose concentration in non-diabetic (A) and 
STZ-induced diabetic (B) rats.  MA (20, 40 and 80 mg/kg) doses were administrated orally to the 
rats twice every third day and the controls animals received DMSO saline. Glucose concentrations 
were measured 6 h following treatment. Values are presented as means, and vertical bars indicate 









Table 6: Comparison of MDA concentration, activities of SOD and GPx in the liver, kidney and 
heart of STZ-induced diabetic rats treated twice every third day for 5 weeks with control non-
diabetic and diabetic animals. Values are expressed as mean ± SEM.  
 
   Organ  
Parameter 
measured 
Treatment Liver Kidney Heart 
 Non-diabetic 
control 
38.40± 4.30 20.42± 6.50 28.40± 4.80 
MDA  STZ-diabetic 
untreated 
46.50±5.20# 41.70±1.60 47.20 ±1.20# 
µmol 
(nmol g-1 protein) 
STZ-diabetic MA 41.60±1.60 25.60±2.60* 45.90±6.40# 
 STZ-diabetic  
Met 
41.70±3.22 11.10±2.80*# 56.00±12.80# 
     
 Non-diabetic 
control 
8.11±0.93  18.34±3.60 3.00±0.14 
SOD STZ-diabetic 
untreated 
1.22±0.02#  5.50±0.10 3.83±0.15 
Activity STZ-diabetic MA  8.16±1.28*# 16.04±0.46* 2.39±0.33 
(nmol/min/mL/g) STZ-diabetic  
Met 
6.53±1.00*#   7.40±1.09* 5.62±1.10*# 
     
GPx Non-diabetic 
control 
26±1 49±6 UNDETECTABLE 
Activity STZ-diabetic 
untreated 
0.34 ±0.04# 7±1*# UNDETECTABLE 
(pmol/min/mL/g) STZ-diabetic MA  25±4*# 44±6*# UNDETECTABLE 
 STZ-diabetic Met 22±7*#  98±3*#  55±8*# 
     
 
* p<0.05 by comparison with respective control animals;  



















This study determined the effects of S. aromaticum derived-MA and related triterpenes derivatives 
on renal function and blood pressure of STZ-induced non-diabetic and diabetic rats with the hope 
of providing evidence for possible use of the compounds in the management of diabetes mellitus. 
The results indicate that MA and the relative derivate PH-MA were effective in ameliorating renal 
fluid and electrolyte handling and expression of renal tubule glucose transporters. The results also 
indicate that MA reduces mean arterial blood pressure of non-diabetic and STZ-induced diabetic 
rats. The findings contextualize the renal, hypoglycaemic and hypotensive effects of S. 
aromaticum derived-MA and related triterpenes derivatives in the management of diabetes.  
 
The results were obtained using plant derived MA and derivatives whose structures were 
confirmed by NMR spectroscopy. Previous studies indicate that MA possess hypoglycaemic 
effects in partially diabetic rats (Liu et al., 2007).  MA was used in this study in an effort to advance 
current knowledge about this triterpene on kidney function. Triterpenes such as MA are generally 
hydrophobic and therefore are difficult to dissolve in water before administration. According to 
Williams et al. poor water solubility is a significant risk factor in low oral absorption because drug 
molecules must completely dissolve in water before oral administration (Williams et al., 2013). 
Therefore, MA derivatives were synthesised in order to improve efficacy of this compound. 
Derivatives were synthesised based on the currently known MA active sites. The first active site 
is the carboxylic group which has previously been shown to be responsible for glycogen 
phosphorylase (GP) inhibition and the second site is which is responsible for PTP1 inhibitor. 
Several derivatives have been synthesized with an effort to improve water solubility of this 
triterpene, as they are well known to have poor water solubility. The results were, however, 
disappointing as incorporation of hydrophilic groups on carbon 28 significantly decreased potency. 
According to Wen et al. introduction of hydrophobic groups (bromobutane) on carbon 28, 
carboxylic groups gives rise to a 7- fold increase effects compared to lead MA (Wen et al., 2006). 
Accordingly, we opted to incorporate hydrophobic groups on c-28 to increase potency of MA. MA 
has, however, been screened for PTP1B inhibition along with isomers such as 3-epi-maslinic acid 
and augustic acid on PTP1B. Among the MA isomers, MA demonstrated good PTP1B inhibition 
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(IC50 = 5.93 µM). Hence our current research also focused on synthesizing MA derivatives with 
an aim to improve solubility, efficacy and bioavailability. To achieve this, a series of heterocyclic 
rings were incorporated in C-2 and C-3 position based on the evidence that heterocyclic 
incorporating heterocyclic rings improved efficacy of MA (Qiu et al., 2009). The synthesis was 
based from previous studies which demonstrated the efficacy of MA derivatives after 
incorporating heterocyclic rings (Qiu et al., 2009) . 
MA was extracted from the ethyl acetate solubles rich in triterpenes (Mapanga et al., 2009). The 
structure of MA and derivatives was elucidated using 1HNMR and 13C NMR spectra compared to 
the previously reported data (Júlio et al., 2003) . The C-2 represents a carbon-OH bond that is 
absent in other triterpenes like oleanolic acid (OA) and ursolic acid (UA) had the resonance shift 
that was identical to previously extracted MA (Júlio et al., 2003) . Additionally, C-12 and C-13 
representing the olefenic bond peculiar to triterpenes served as a confirmation that the compound 
was indeed a triterpene and the carbon signal was identical to previously extracted MA (Júlio et 
al., 2003). This information confirms our previous findings that Syzygium species are rich in 
triterpenes mixtures. Fischer indole synthesis was used for synthesis of MA derivatives from OA. 
Fused heterocyclic derivatives of triterpenes and alkaloids are well documented (Heather et al., 
2000) and biologically active indole-fused examples are of particular interest. Our syntheses of the 
target compounds PH-MA, Cl-PH and F-PH are based on the Fischer indole synthesis (Claas et 
al., 2007; Qiu et al., 2009). The 1HNMR for PH derivative indicates that there were four singlets, 
three duplets and three multiplets which were comparable to that of (Finlay et al., 2002). Indeed, 
Fl-PH and CL-PH had the similar number of singlets and dublets with an addition of corresponding 
resonance peaks for flouro and chlouro. These results, therefore, indicate the authenticity of our 
fused-heterocyclic triterpene derivatives. The GP inhibitors were all insoluble in water even after 
preparing in DMSO, indicating that introduction of hydrophobic rings does indeed influence 
solubility of compounds.  
 
Experimental diabetes was induced with a single intraperitoneal  STZ  (60 mg/kg) injection which 
selectively destroys or impairs secretion of insulin from pancreatic β- cells and the systemic 
changes which occur following this are related to the induced diabetic state (Li et al., 2005; 
Lenzen, 2008). Indeed, untreated STZ-diabetic rats exhibited significantly low plasma insulin 
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concentration and increased plasma glucose concentrations compared to non-diabetic rats perhaps 
due to destruction of pancreatic β-cells (Pinent et al., 2004; Lenzen, 2008). This was also in 
agreement with previous immunohistological studies which showed complete obliteration 
pancreatic β- cells by STZ injection (Coskun et al., 2005). STZ is translocated in cells through the 
GLUT2 transporter to crosslink the vital structure (Beckman et al., 1990; Kroncke et al., 1991). 
Oxygen free radicals and superoxide dismutase have also been shown induce toxicity of pancreatic 
β cells (Wohaieb and Godin, 1987) . We were, therefore able to investigate the effects of the extract 
without an influence of insulin secretion, mimicking type 1 diabetes. 
 
STZ-induced diabetic rats exhibited weekly decreases in urinary Na+ excretion and elevated 
plasma creatinine concentration at the end of five weeks with concomitant reduction in GFR. We 
suggest that the impaired renal function in diabetic animals was not due to the STZ nephrotoxicity 
since the dose of STZ (60 mg/kg) used to induce diabetes has been reported to have minimal kidney 
toxicity in experimental animals (Kuramochi and Homma, 1993; Koulmanda et al., 2003; Lenzen, 
2008). Chronic hyperglycaemia due to diabetes mellitus leads to several kidney complications 
which include Na+ retention, reduction in glomerular filtration rate (GFR) and elevation of blood 
pressure presumably due to elevated oxidative stress (MDA levels) (Stengel et al., 2003; Magri 
and Fava, 2009; Raju et al., 2013). These effects eventually lead to renal failure and hence death 
of diabetic patients (Nangaku, 2006). Indeed, impaired renal dysfunction has long been associated 
with experimental diabetes (Musabayane et al., 1995). Laboratory evidence indicates that MA and 
PH do not only reduce blood glucose concentration, but also exhibit beneficial effects in the kidney 
through amelioration of GFR and increased Na+ excretion rate in those animals that have been 
observed to retain Na+. GFR is the important marker for kidney function and correlation between 
urinary Na+ excretion and GFR has been reported by other authors (Satirapoj et al., 2006 ; Hoek 
et al., 2008). GFR was assessed by creatinine clearance (Ccr) which has been extensively used in 
our laboratory and other researchers to evaluate renal tubular function (Rebsomen et al., 2005; 
Kumar et al., 2008; Mapanga et al., 2009; Madlala et al., 2012). An increase in GFR by triterpenes, 
particularly OA has indeed been reported in our laboratory (Madlala et al., 2012). MA is clinically 
used as an anti-tumour drug (Li et al., 2010) which means this triterpene may increase cell viability 
in the kidney. This was confirmed by the ability of MA to increase cell viability in MDBK cells, 
indicating that the natriuretic effects were not associated with nephrotoxicity. Although PH-MA 
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exerted toxicity after 24 and 48 h treatment, we suspect that the doses used in this study were very 
high. Hence for acute studies, relatively low doses of PH-MA were used compared to that of MA. 
A decrease in GFR is also associated with increased reabsorption of Na+ mainly in proximal 
tubule’s sodium hydrogen transporter (NHE3) (Vallon et al., 1999). The data obtained in this 
suggest that the beneficial effects of MA in diabetes mellitus are complimentary. Our results 
showed that the elevated concentrations of MDA (marker of lipid peroxidation) in diabetic rat 
tissues of the liver, kidney and were restored within normal values after treatment with MA after 
5-weeks. The reduction in MDA levels could be due to the improvement in glycaemic control and 
also increased antioxidant status, since MA significantly stimulated increased activities of SOD 
and GPx. Studies indeed show that tight reduction of blood glucose may prevent oxidative stress 
and therefore delay the onset of diabetic complications (Brosius and Heilig, 2005). The increase 
in lipid peroxidation products due to hyperglycaemia has been previously reported in tissues of 
diabetic rats and suggested to partly contribute to long term kidney damage (Raju et al., 2013). 
MA has previously been shown to decrease nitric oxide levels, another potent tissue damage 
oxidant, therefore supporting our current findings (Montilla et al., 2003). MA attenuated these 
changes mediated possibly in part via enhancement of the antioxidant status thus supporting 
previous reports that extracts containing MA reduce the severity of kidney dysfunction in diabetes 
(Xu et al., 2009). Furthermore, Yamabe et al. reported that antioxidants and good control of 
diabetes led to improved renal function. Thus, oxidative stress could, at least partially, play a 
central role in cardio-renal dysfunction in diabetes (Yamabe et al., 2006). Against these 
observations are reports of the absence of improvement and even worsening of diabetic 
nephropathy with antioxidant treatment (Agardh et al., 1992). Diabetic nephropathy has indeed 
been observed unregulated diabetes characterized by increased expression of GLUT1, and 2 in 
proximal (Marks et al., 2003)  and distal tubule (Linden et al., 2006). Interestingly, treatment with 
MA for 5-weeks decreased GLUT1 and GLUT 2 expressions in the kidneys of diabetic rats to 
perhaps reduce urinary glucose leak. In the absence of urinary glucose measurements, further 
studies are clearly needed to support this speculation. The renal reabsorption of glucose which 
occurs mostly in the proximal tubule involves luminal Na+ glucose transporters (SGLTs) and 
facilitative diffusion through GLUT1 and GLUT2 in the brush border membrane (Thorens et al., 
1990). In diabetic animals insertion of GLUT2 into the brush border membrane of the proximal 
tubule is stimulated thereby increasing facilitative glucose uptake (Marks et al., 2003) . 
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Interestingly, cell culture studies indicate that MA inhibited glucose uptake by MDBK cells which 
correlates with results obtained chronically whereby MA abolished expression of GLUT1 and 2 in 
diabetic kidneys. MA has indeed been shown to reduce glucose absorption by decreasing the levels 
of SGLT and GLUT2 in the small intestines of STZ-induced (Khathi et al., 2013). Interestingly 
both MA (Liu et al., 2007) and metformin (Stumvoll et al., 1995 ) have been shown to reduce 
plasma insulin in diabetic animals. Moreover, among other triterpenes such as OA and UA, MA 
and PH have previously been shown to selectively inhibit PTP1B expression which leads to 
increased insulin sensitivity. This could be another mechanism through which these triterpenes 
(MA and PH) improve kidney function. Indeed, the tight glycaemic control and kidney 
ameliorative properties of triterpenes has previously been shown in previous studies (Madlala et 
al., 2012) . Additionally, MA treatment also increased GLUT4 expression in the skeletal muscle 
of diabetic rats suggesting reduced blood glucose concentration by this triterpene is indeed linked 
to renal function. Studies indicate that hyperglycaemia is the main cause of decline in renal 
function in diabetic patients (Gnudi et al., 2007).  
Our aim to improve efficacy solubility and efficacy of MA had proven to be successful as PH was 
more effective in improving glucose homeostasis in liver cell lines. This was indeed in agreement 
with previous researcher whereby PH derivatives exhibited 7-fold effects against protein tyrosine 
phosphatase when compared to MA (parent compound) (Qiu et al., 2009).  Treatment with MA 
stabilized body weight of STZ-induced diabetic rats, this could be biological importance as 
diabetic patients are known to lose weight over time.  The decrease in weight could be due to 
hypoglycaemic properties of MA. 
This study also attempted to clarify the effects of MA and PH-MA on proximal tubule Na+ 
handling and using lithium clearance as a marker, a technique that is widely used in animal studies 
to assess proximal tubular function (Boer et al., 1995). Acute administration of MA, PH-MA, F-
PH and Cl-PH increased urinary Na+ output in STZ-induced diabetic animals. This increase in Na+ 
was in concomitant with FENa
+ and FELi
+ in anaesthetised non-diabetic and STZ-induced diabetic 
animals. CLi
+ was used to estimate the amount of Na+ in the proximal tubules. Renal CLi
+ studies 
have been widely used to estimate proximal tubular function in both animals and mammals 
(Koomans et al., 1989; Shirley and Walter, 1990; Walter and Shirley, 1991). Renal CLi+ technique 
is based on the fact that Na+ is reabsorbed at the similar rate as Li+.. Studies  conducted by five 
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different researchers, have however, indicated that most of the Li+ is reabsorbed in the proximal 
tubule at a range of 73 to 82% of the whole kidney (Gutman et al., 1973; Hayslett and Kashgarian, 
1979; Thomsen et al., 1981; Thomsen et al., 1981; Haas et al., 1986; Kirchner, 1987). Oliveria et 
al. showed that insulin increased urinary Na+ output with a concomitant increase in FELi+ and FENa+ 
that on STZ-diabetic rats (Oliveira et al., 2010) . This evidence also suggests that Li
+ is indeed an 
ideal marker for Na+ handling in the proximal tubule. Our results indicate that MA and PH-MA 
evoked increase in FENa
+ without GFR resulted in increased proximal tubular Na+ excretion of 
non-diabetic rats. However, a significant increase in GFR was observed in STZ-induced diabetic 
rats. These results, therefore, suggest that MA and PH-MA influences Na+ handling in this segment 
of the nephrons. An increase in FENa
+ and FELi
+ suggests that the triterpenes inhibit proximal 
tubular reabsorption of Na+ hence resulting in a pronounced increase in urinary Na+ excretion. The 
exact mechanism (s) and transporters that are involved in impaired proximal tubular Na+ 
reabsorption could not be elucidated in this study. The proximal tubules reabsorbs about 70% of 
total filtered Na+. The reabsorption involves coupling of Na+ entry via sodium-proton exchanger 
type 3 (NHE3) transporters where by the Na+ extrusion primarily occurs through Na+-K+-ATPase 
(Cai et al., 2008). Another important transporter found in the proximal tubule is sodium-
bicarbonate co-transporter (NBCe1) which mediates Na+ exit from the tubular cells (Horita et al., 
2011). We, therefore, speculate that MA may be involved in inhibiting apical NHE3 and 
basolateral Na+-K+-ATPase stimulated basolateral NBCe1 transported which accounts for the exit 
of Na+ from the proximal tubular. MA and PH-MA possible inhibit these transporters in a way that 
favours increase Na+ output seen in experimental animals. Research conducted in hypertensive rats 
showed an increase in expression of apical NHE3 also increased absorption of Na+ in the proximal 
tubule (Anne et al., 2009). However, drugs like a-adrenoceptor agonists and inhibitory parathyroid 
hormone (PTH) regulate NHE3 and therefore, Na+ reabsorption (Gesek et al., 1989) . To further 
elucidate the mechanism of action the effects of MA and PH-MA on expression of ENaC 
transporter were investigated in the distal tubule cells. Our results suggest that MA and PH-MA 
also increase Na+ excretion by attenuation ENaC expression in distal tubule cells with PH showing 
more efficacy than the parent compound.  In the kidney distal nephron and collecting duct sodium 
entry from the lumen into the cells is mediated by the amiloride-sensitive sodium channel, ENaC 
at the apical membrane (Duc et al., 1994) and the Na, K-ATPase at the basolateral membrane, 
which provides the driving force for apical sodium reabsorption. Studies by O’Neill et al. showed 
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that STZ-induced diabetic rats exhibit a marked increase in ENaC expression which in concomitant 
with increased plasma AVP (O'Neill et al., 2008). This was indeed in agreement with the observed 
increases in plasma for our STZ-induced diabetic animals, although MA and PH-MA reduced AVP 
to values that did not reach significance. However, this could be of biological importance. Na+ 
reabsorption by ENaC is also known to be regulated by aldosterone (Masilamani et al., 1999). The 
results of this study also show that aldosterone levels were elevated in STZ-induced diabetic rats. 
In contrast MA and PH-MA decreased plasma aldosterone with a concomitant decrease in ENaC 
expression. This outcome of MA and PH-MA was similar to that of amiodipine which was shown 
by other researchers to decreased plasma aldosterone, attenuate oxidative stress and thus 
ameliorates diabetes induced renal injury via (Matavelli and Siragy, 2013). Our cumulative data 
revealed that PH was more effective in ameliorating acute kidney function as shown by significant 
increased Na+ excretion. A large number of heterocyclic indole derivatives have been shown to 
have improved pharmacological effects when compared to parent compounds (Wagaw et al., 
1998). Indeed, PH has previously been shown to possess 7 times fold efficacy on PTPB1 inhibition 
by comparison to lead MA, therefore, correlating to our current findings (Qiu et al., 2009).  
In addition to Na+ renal function studies, the effects of MA were also investigated on MAP of non-
diabetic and STZ-induced diabetic rats. MA significantly reduced MAP, this effect has previously 
been reported in triterpenes like UA (Somova et al., 2003) and OA (Mapanga et al., 2009) in Dahl 
sensitive and STZ-induced diabetic rats, respectively. The results are of significant importance as 
it is well know that diabetes leads to high blood pressure that eventually results in cardiovascular 
complications  (Cooper et al., 2006; Kanetsuna et al., 2006). The mechanism by which MA 
lowered MAP was not elucidated in this study. 
 
 In addition, this study shows for the first the efficacy of MA in reducing the mean arterial blood 
pressure of STZ-induced diabetic rats. The findings contextualize the renal, hypoglycaemic and 
hypotensive effects of S. aromaticum derived-MA and related triterpenes derivatives in the 







5.0 Conclusions  
 
The results described in this study demonstrate that the S. aromaticum-derived MA and related 
triterpene derivatives improve kidney function associated with diabetes mellitus. Additionally, this 
study indicates for the first time that MA reduced blood pressure while exerting no toxic effects to 
the kidney and liver cell lines.  Taken together, the results suggest that MA and PH-MA indeed 
may alleviate some complications associated with diabetes mellitus.  
 
5.1 Limitations of the study 
 
This study only investigated the effects of MA and PH-MA on proximal and distal tubular Na+ 
handling. Other parameters such as blood pressure were not determined for PH and higher doses 
of PH-MA were used for cell viability studies. The effects of PH-MA were only investigated 
acutely for Na+ handling studies, the effects of PH chronically remain unknown.  
 
5.2 Future recommendations   
 
The future studies should, therefore, investigate the effects of MA and PH-MA on Na+ handling 
in other segments of the kidney. Future studies should also investigate the chronic effects of PH-
MA on Na+ handling and blood pressure. In addition, for toxicity studies lower doses of PH-MA 
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APPENDIX III: Conference presentations 
Endocrine Abstracts (2012) 28 P207 
Effects of Syzygium aromaticum-derived maslinic acid on blood glucose of streptozotocin 
induced-diabetic rats 
Blessing Mkhwanazi1, Andile Khathi1, Masola Bubuya2, Fanie van Heerden3 & Cephas 
Musabayane1 
Available evidence suggests that Syzygium spp ethyl acetate solubles (EAS) contain triterpene 
mixtures (oleanolic/ursolic acid and methyl maslinate/methyl corosolate) with hypoglycaemic 
properties in streptozotocin (STZ)-induced diabetic rats. Accordingly, maslinic acid (MA) was 
isolated from S. aromaticum. Air-dried powdered flower buds of S. aromaticum were sequentially 
extracted thrice at 24 h intervals with 3 litres on each occasion of hexane, dichloromethane, ethyl 
acetate and methanol. The stereostructure of MA obtained following recrystallization with 
chloroform and methanol was elucidated by 1 h- and 13C-NMR spectroscopy (1D and 2D) on 
chemical and physicochemical evidence. Oral glucose tolerance (OGT) responses to various doses 
of MA (20, 40 and 80 mg.kg-1, p.o.) were monitored in non-diabetic and STZ-induced diabetic 
rats after an 18-h fast. Rats treated with deionized water or metformin acted as untreated and 
treated positive controls, respectively. Blood glucose concentrations were measured at 15-min 
intervals for the first hour, and hourly thereafter for 3 h. Short-term effects were monitored after 6 
h in animals treated with MA twice daily by means of a bulbed steel tube for a period of 5 weeks 
while, food and water intake as well as body weight were monitored 24 hours after treatment every 
third day. All results are presented as mean± standard error means where P<0.05 denotes statistical 
significance. All doses of MA significantly decreased blood glucose of non-diabetic and STZ-
induced diabetic rats throughout the experimental period. Comparisons of the blood glucose 
lowering effects of the MA doses at each time appeared to be dose-dependent in STZ-induced 
diabetic rats. MA administration reduced the body weight loss of STZ-induced diabetic rats 
without altering food intake. The results suggest that MA, like metformin, contains blood glucose 
lowering properties suggesting that it is a potential drug for the management of type 1 diabetes 
mellitus. 
Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the 
impartiality of the research reported. 
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The effects of Syzygium aromaticum-derived oleanolic acid on reactive oxygen species in the 
heart, liver and kidney of STZ-induced diabetic rats 
Blessing Mkhwanazi, Ntethelelo Sibiya, Metse Serumala, Rene Myburg & Cephas T 
Musabayane 
 
The onset of diabetic complications is attributed to sustained hyperglycemia which triggers the 
generation of free radicals and oxidative-related damage in the retina, renal glomerulus and 
peripheral nerves. Recent studies report that intense glycaemic control by the subcutaneous 
administration of insulin cannot completely restore the balance between reactive oxygen species 
and antioxidants. Preliminary studies in our laboratory indicate that transdermally delivered 
Syzygium aromaticum-derived oleanolic acid (OA) has the ability to lower blood glucose in 
experimental diabetes mellitus due to the sustained release of the triterpene. However, no work 
has been done to determine the effects of OA on reactive oxygen species (ROS). Research has 
indicated that some bioactive compounds such as flavonoids and tannins have antioxidant 
properties. Accordingly, this study was designed to investigate and evaluate the effects of S. 
aromaticum-derived OA on ROS levels. The acute effects of OA were evaluated on 
malondialdehyde (MDA) and glutathione (GSH) concentrations in STZ-induced diabetic rats 
following a glucose load after an 18-h fast. Rats administered pectin-free OA or transdermally 
delivered insulin acted as untreated and treated positive controls, respectively, while non-diabetic 
rats served as absolute controls. The transdermal patches were applied for 6 h, thereafter the 
animals were sacrificed. The heart, liver and kidney were collected for ROS biomarkers (MDA) 
and antioxidants (GSH) analysis. MDA levels were significantly reduced in the heart (233.0±0.1 
vs 47.0±0.1 nmol/l) and liver (233.0±0.1 vs 130.0±0.1 nmol/l). Interestingly, GSH levels were also 
significantly increased in the heart (196.0±0.4 vs 313.0±0.5 nmol/l). These results suggest that S. 
aromaticum-derived OA is potentially effective in ameliorating the oxidative stress observed in 
diabetes mellitus in the heart. It can therefore, be concluded that OA is a potential drug for diabetes 
mellitus that would not only lower blood glucose but also can avert complications that arise due 
to oxidative stress. 
Declaration of funding: This study was partly funded by the NRF South Africa and the University 
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1HNMR for F-phenly hydrazine derivative  
 
 
 
 
 
 
